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Objectives
From the first description by Leo Kanner [1], autism has been an en-
igmatic neurobehavioral phenomenon. The new genetic/genomic
technologies of the past decade have not been as productive as ori-
ginally anticipated in unveiling the mysteries of autism. The specific
etiology of the majority of cases of autism spectrum disorder (ASD) is
unknown, although numerous genetic/genomic variants and alter-
ations of diverse cellular functions have been reported. Prompted by
this failure, we have investigated whether the metabolomics ap-
proach might yield results which could simultaneously lead to a
blood-based screening/diagnostic test and to treatment options.
Methods
Plasma samples from a clinically well-defined cohort of 100 male in-
dividuals, ages 2-16+ years, with ASD and 32 age-matched typically
developing (TD) controls were subjected to global metabolomic
analysis.
Results
We have identified more than 25 plasma metabolites among the ap-
proximately 650 metabolites analyzed, representing over 70 bio-
chemical pathways, that can discriminate children with ASD as
young as 2 years from children that are developing typically. The dis-
criminating power was greatest in the 2–10 year age group and
weaker in older age groups. The initial findings were validated in a
second cohort of 83 children, males and females, ages 2–10 years,
with ASD and 76 age and gender-matched TD children. The discrim-
inant metabolites were associated with several key biochemical path-
ways suggestive of potential contributions of increased oxidative
stress, mitochondrial dysfunction, inflammation and immune dysreg-
ulation in ASD. Further, targeted quantitative analysis of a subset of
discriminating metabolites using tandem mass spectrometry pro-
vided a reliable laboratory method to detect children with ASD.
Conclusion
Metabolic profiling appears to be a robust technique to identify
children with ASD ages 2–10 years and provides insights into the
altered metabolic pathways in ASD, which could lead to treatment
strategies.
References
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Objectives
To uncover novel traits associated with nicotine and alcohol use gen-
etics, we performed a phenome-wide association study in a large
multi-ethnic cohort.
Methods
We investigated 7,688 African-Americans (AFR), 1,133 Asian-Americans
(ASN), 14,081 European-Americans (EUR), and 3,492 Hispanic-Americans
(HISP) from the Women’s Health Initiative, analyzing risk alleles located
in the CHRNA5–CHRNA3 locus (rs8034191, rs1051730, rs12914385,
rs2036527, and rs16969968) for nicotine-related traits and ADH1B
(rs1229984 and rs2066702) and ALDH2 (rs671) for alcohol-related traits
with respect to anthropometric characteristics, dietary habits, social sta-
tus, psychological circumstances, reproductive history, health condi-
tions, and nicotine- and alcohol-related traits.
Results
The investigated loci resulted associated with novel traits: rs1229984
were associated with family income (p=4.1*10−12), having a pet
(p=6.5*10−11), partner education (p=1.8*10−10), “usually expect the best”
(p=2.4*10−7), “felt calm and peaceful” (p=2.6*10−7), education (p=3.7*
10−6), and number of term pregnancies (p=1.12*10−5) in EUR; rs1051730
and rs16969968 showed a suggestive association with “High cholesterol
requiring pills ever” (p=3.8*10−4 and p=1.8*10−4) in trans-ethnic meta-
analysis. We also replicated the known associations: rs80341911 was as-
sociated with cigarettes per day (CIGSDAY, p=3.4*10−8), smoking status
(p=6.7*10−3), and “smoked at least 100 cigarettes” (p=7.3*10−3) in EUR;
rs1051730 and rs16969968 were associated with CIGSDAY (p=9.1*10−8
and p=1.1*10−7) and lung cancer (p=7.3*10−3 and p=9.9*10−3) in EUR;
rs2036527 was associated with CIGSDAY (p=3.5*10−3) in AFR; rs1229984
showed associations for alcohol servings (ALC, p=2.9*10−6), beer servings
(p=3*10−6), wine servings (WINE, p=3.9*10−6), liquor servings (p=5.5*
10−6), dietary alcohol (DIETALC, p=6.1*10−6), “Drinks alcohol (age 50)”
(p=9.3*10−6) in EUR and for ALC (p=5.2*10−5) and DIETALC (p=9.6*10−5)
in HISP; rs671 resulted associated with alcohol intake (p=3.8*10−8),
DIETALC (p=1.9*10−7), ALC (p=1.3*10−6), WINE (p=1.1*10−5) and “Drank
12 alcoholic beverages ever” (p=1.2*10−5) in ASN.
Conclusion
We provided novel genetic data regarding the consequences of smok-
ing and drinking behaviors and confirmed ethnic differences in their
genetic predisposition.
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Objectives
Prenatal environment and genetic polymorphism can have a lasting
impact on offspring’s metabolic function by perturbing its epige-
nome. Birth weight is often used as a surrogate for the overall qual-
ity of the intrauterine environment. We present the first neonate
epigenome-wide association study in an Asian mother-offspring co-
hort, that interrogates the effects of prenatal environment variables,
umbilical cord DNA methylation and SNPs, on birth weight.
Methods
In GUSTO, a prospective mother-offspring cohort study (N=987), we
examined the associations between DNA methylation, SNPs, birth
weight and 11 prenatal environment variables. First, we investigated
the association between perinatal methylome and birth weight to
identify sites of variability in methylation. Second, we interrogated
the contribution of genetic and prenatal environmental factors on
this variability in the epigenome. Finally, we examined whether these
methylation marks at birth were associated with offspring size and
adiposity in early childhood.
Results
Methylation levels at 50 CpGs were significantly associated with birth
weight, and a subset of these CpGs was located in genes and miRNA
known to be involved in metabolic pathways/disorders. We further
examined the influence of environmental and genetic factors on
methylation at these 50 CpG sites. Sixteen CpGs were associated with
both, an additional 24 CpGs were associated with only environmental
factors, while only 3 CpGs were associated with genetic factors alone.
Environmental factors associated with methylation were predomin-
antly maternal-adiposity-related (pre-pregnancy body mass index,
pregnancy weight gain and maternal glucose levels). Methylation
levels at half of these CpGs were also associated with offspring size
and adiposity in early childhood.
Conclusion
Developmental pathways to obesity begin before birth and involve
genetic, epigenetic and environmental factors.
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Objectives
Genome-wide association studies (GWAS) have indicated that se-
quence variation in cis-regulatory elements (CRE) plays important
roles in common disease risk/trait variation, but identification of
these causal variants has remained a major challenge in complex
trait genetics. Here, we performed reporter assays for all common
variants at the QT interval associated SCN5A GWAS locus, with the
goal of identifying the underlying causal variants.
Methods
A target region of ~500kb at SCN5A was defined based on recombin-
ation hotspots (rate>10cM/Mb; HapMap) flanking the 5 independent
QT interval GWAS hits. Within the target region, all common variants
(minor allele frequency >5%) from the 1000 Genomes European an-
cestry populations in moderate linkage disequilibrium (r2>0.3) with
any of the 5 GWAS hits were selected. Both alleles of these variants
were amplified with flanking sequences and cloned upstream of a
minimal promoter driven firefly luciferase gene in pGL4.23. Human
cardiomyocyte cells, AC16, were transfected with test constructs and
Renilla luciferase vector (for transfection normalization) in triplicate
and luciferase assays were performed 24h later. Reporter assays on a
subset of variants were repeated for assessing allelic difference in
regulatory activity. All cloning and reporter assays were performed in
96- and 24-well plates.
Results
Of a total 121 variants selected, 112 variants in 104 amplicons passed
primer design (amplicon size 256-617bp; median 397bp), and we
successfully cloned both alleles for 106 variants in 98 amplicons. In
reporter assays, compared to empty vector, 24 and 40 amplicons
showed enhancer (>2-fold) and suppressor (<0.5-fold) activities in
AC16 cells, respectively. Of these only 4 were observed as open chro-
matin regions in heart tissue in NIH Epigenomics data. Overall, 12
variants showed nominally significant allelic difference (P<0.05) in re-
porter activity and were repeated with 18 replicates and 7 variants
were identified to have repeated significant allelic difference in regu-
latory activity.
Conclusion
Independent of the available epigenomic data, which are of limited
relevance, an unbiased in vitro reporter screen for CREs overlapping
all common variants associated with QT interval at the SCN5A GWAS
locus identified 7 common cis-regulatory variants. Our immediate
next goals are to a) evaluate the effect of deleting these 7 CREs on
SCN5A expression in AC16 cells and b) identify the trans-acting fac-
tors regulating their functions.
Disclosure of interest
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Objectives
Some cancers show a strong tendency to metastasize to bone, a tissue
of mesenchymal origin and a prominent site of mesenchymal stem
cells (MSC) residing in the stem cell niche. With bone metastasis forma-
tion being one of the most detrimental steps in cancer progression, a
better understanding of how bone metastases are initially formed is
key to successfully targeting bone metastasis of, for example, prostate
cancer. Recent reports have suggested that bone-metastasizing cancers
may mimic the process of homing of hematopoietic stem cells to their
bone niche.
Methods
In order to understand the role of MSC in metastasis formation, we
investigated the interaction of primary human bone marrow MSC
with established cancer cell lines able to metastasize to bone. With a
trans-well migration assay we could show that MSC induced a rapid
migration response of prostate and breast cancer cell lines already
within two hours after start of the experiment. In order to identify
factors stimulating cancer cell migration, MSC cell culture super-
natant was separated by size exclusion and ion exchange chroma-
tography. Migratory fractions then were further analyzed by mass
spectrometry and antibody array analysis.
Results
With this approach we identified the extracellular matrix proteins
type I and type III collagen, fibronectin and laminin 421 as potential
drivers of cancer cell migration, which was confirmed by using re-
combinant proteins. RNAi experiments showed that the cancer cell
extracellular matrix receptor beta 1 integrin obviously plays a pivotal
role for cell migration.
Conclusion
From our results we conclude that the extracellular matrix as it is
produced by MSC obviously plays a crucial role for cancer metastasis
and therefore might be a promising anti-cancer drug target.
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Objectives
Trisomy 21 is a model disorder of altered gene expression. We have
previously used a pair of monozygotic twins discordant for trisomy
21 to study the global dysregulation of gene expression, without the
noise due to genetic variation among individuals (Nature:508; 345–
350;2014). The majority of previous studies focused on aneuploidies
were conducted οn cell populations or tissues. Our study focusing on
gene and allelic expression behaviour of single cells (SC), aims to re-
veal biological insights regarding the cellular impact of aneuploidy
and uncover the mechanisms of gene dosage.
Methods
We estimated the allele specific expression (ASE) from RNAseq of
~1000 single cells in different aneuploidies. We used 352 SC fibro-
blasts (173 Normal and 179 T21 cells) from the pair of monozygotic
twins discordant for T21, 166 SC from a mosaic T21, 176 SC from a
mosaic T18, 151 SC from a mosaic T8, and 146 SC from a mosaic T13.
Results
In the monozygotic twins, a considerable number of heterozygous
sites at the non-chr21 genome showed monoallelic expression (MAE);
(Normal: 73.5 % monoallelic in 564,668 observations, and T21: 78.7 %
monoallelic in 549,799 observations). There was also considerable MAE
for chr21 sites in Normal and, surprisingly, in T21 cells as well (Normal:
63,3 % monoallelic in 5,009 observations, and T21: 72.8 % monoallelic
in 6,456 observations). We classified the genes on chr21 in 3 classes ac-
cording to the level of the aggregate MAE of their corresponding sites
(9 monoallelic, 29 intermediate, 2 biallelic). Similar results, i.e. extensive
MAE on the supernumerary chromosome genes, were also observed in
the other aneuploidies.
Conclusion
We hypothesize that each class of genes contributes in a specific
way to the phenotypic variability of Down Syndrome. Our analysis
showed that, for genes with monoallelic expression, the abnormal
gene dosage induced by the aneuploid chromosome is maybe due
to the number of cells expressing the gene. This difference in the
fraction of expressing cells could contribute to the development and
the variability of phenotypes in aneuploidies. This study provides a
new fundamental understanding of the allele specific expression in
T21 and other aneuploidies.
Disclosure of interest
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Objectives
A large number of EBV immortalized lymphoblastoid cell lines (LCLs)
have been generated and maintained in genetic/epidemiological
studies as a perpetual source of DNA and as a surrogate in-vitro cell
model. Recent successes in reprograming LCLs into induced pluri-
potent stem cells (iPSCs) have paved the way to generate more
relevant in-vitro disease models using this existing bio-resource.
However the effects of EBV encoded oncoproteins on cellular tran-
scription and function make LCLs a unique biomaterial to re-
programme. Accumulating evidence now provides support that
miRNAs play a critical role in transcription factor-induced repro-
gramming of iPSCs.
Methods
To investigate the role of miRNAs in regulating gene expression and
cellular functions during LCL to iPSC reprogramming, we performed
a parallel genome-wide miRNA and mRNA expression analysis in six
LCLs and their reprogrammed iPSCs.
Results
A total of 77 miRNAs and 5,228 mRNAs were significantly (FC-abs ≥
2.0 and FDR ≤ 0.05) differentially expressed (DE) during LCL to iPSC
reprogramming out of which 29 miRNAs and 2,317 mRNAs were sig-
nificantly down-regulated and 48 miRNAs and 2,911mRNAs were sig-
nificantly up-regulated. The down-regulated miRNAs were highly
enriched for LCL specific miRNAs (miR-155, let-7a-i, miR-21, miR-142,
miR103, miR-320, miR-146a-b) and the up-regulated miRNAs were
highly enriched for iPSC specific miRNAs (miR-302a, miR-302c, miR-
371a, miR-302b, miR-302d, miR-372, miR-373miR-92a-1, miR-92a-2,
miR-92b, miR-17, miR-20a, miR-18a). Further we performed target pre-
diction analysis for all the significantly DE miRNAs using the miRNA
target prediction data bases. The 3,456 genes were predicted to be
the targets of the 29 miRNAs that were significantly down-regulated
during LCL to iPSC reprogramming. Out of these 3,456 predicted tar-
get genes 1,023 were significantly DE during LCL to iPSC reprogram-
ming. For the 48 miRNAs that were significantly up-regulated during
LCL to iPSC reprogramming 5,063 target genes were predicted out of
which 1,462 were significantly DE during LCL to iPSC reprogramming.
Human Genomics 2016, Volume 10 Suppl 1 Page 3 of 40
The significantly DE genes that were also the predicted targets of the
significantly down or up regulated miRNAs were further analyzed for
functional annotations and pathway analysis using Ingenuity Path-
way Analysis Platform.
Conclusion
In summary, our analysis identifies DE miRNAs and their DE target
genes and a global role of miRNAs in broad resetting of cellular tran-
scriptome and function during LCL to iPSC reprogramming.
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Objectives
Common sequence variation in cis-regulatory elements (CREs) are
the suspected etiological causes of complex disorders. We exam-
ined all common (>10% minor allele frequency) non-coding vari-
ants within a ~153kb locus surrounding the gene for receptor
tyrosine kinase RET, which is most commonly mutated in Hirsch-
sprung disease (HSCR or congenital aganglionosis), a form of func-
tional intestinal obstruction in neonates (1 in 5,000 live births). We
hoped to find all causal non-coding polymorphisms disrupting en-
hancer function leading to the disease.
Methods
We used human and mouse fetal gut at relevant developmental time
points for transcriptional profiling, ChIP assays, transgenic enhancer
assays and siRNA mediate knockdowns of relevant transcription
factors.
Results
We demonstrate that: (i) the three polymorphisms residing in 3 dis-
tinct enhancers that increase risk of the disease by 4-, 2- and 1.7-fold.
Haplotypes for these three independent variants display wide vari-
ation in risk. (ii) the three CREs are Ret enhancers with distinct tem-
poral activities during mouse gut development; (iii) the CREs are
bound by the transcription factors Rarb, Gata2/3 and Sox10, respect-
ively, each developmentally expressed concordant with its cognate
enhancer activity; (iv) variants in these CREs lead to their loss of ac-
tivity and reduce Ret expression; (v) Ret is a positive feedback regula-
tor of Sox10 and Gata2/3 transcription; and, (vi) additional feedback
interactions affect its ligand Gdnf, co-receptor Gfra1 and signal ter-
minator Cbl.
Conclusion
These results explain how individually common, small effect non-
coding polymorphisms can lead to large genetic effects in HSCR,
since transcription attenuation of Ret from enhancer mutations are
amplified through its auto-regulation. These results implicate RET
as a key rate limiting step in early enteric nervous system (ENS) de-
velopment and explains why >95% of HSCR cases have at least one
RET loss-of-function allele. More generally, the phenotypic impact
of a complex disorder can only be understood by assessing gene
effects in the context of their gene regulatory networks.
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Objectives
In individuals presenting with undifferentiated phenotypes such as
developmental delay, hypotonia, and seizures, the list of differential
diagnoses is often very long and includes metabolic/neurometabolic,
genomic, and other Mendelian disorders. Here we want to demon-
strate the utility of untargeted metabolomic profiling to screen for a
wide range of neurometabolic disorders.
Methods
Untargeted small molecule metabolomic profiling was performed as
described previously [1] on plasma samples from 12 patients sus-
pected to have a neurometabolic disorder with a presentation of sei-
zures, developmental delay and hypotonia.
Results
We identified 5 different neurometabolic disorders in these 12 patients.
We observed elevations of 3-methoxytyrosine and decreased levels of
dopamine and vanillylmandelate in AADC deficiency, elevations of 2-
pyrrolidinone in ABAT deficiency, elevations of succinyladenosine in
ADSL deficiency, increased citrate in citrate transporter deficiency, and
elevations of imidazole propionic acid, cis and trans-urocanate in uroca-
nase deficiency. The perturbations in the metabolomic profiles of plasma
from these patients are unique, specific and not previously seen in over
300 other samples analyzed as normal controls or for other indications.
Conclusion
The standard diagnostic test for AADC, ABAT, and ADSL deficiency is
CSF neurotransmitter analysis, while testing for urocanase deficiency re-
quires an enzyme activity assay from a liver biopsy. These cases dem-
onstrate the ability of untargeted metabolomic profiling for the
functional confirmation of pathogenicity of VUS found via WES; more-
over, disorders for which there is no biochemical testing or where test-
ing is only available on CSF are able to be diagnosed in a plasma
sample. This also demonstrates the utility of metabolomic profiling
alone to screen for a wide range of neurometabolic disorders.
References
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Objectives
Alzheimer’s disease (AD) is the most common progressive neurode-
generative disease and represents a major cause of disability for eld-
erly patients. DNA methylation–are increasingly seen as playing an
important role in AD development. However its causal mechanisms
remain unclear. Recent studies indicate that AD develops essentially
as a result of dysfunction of molecular networks. Our purpose is de-
velop large-scale causal methylation networks to uncover the mech-
anism of AD development.
Methods
We propose to use causal graphs as a major concept and a general
framework for causal methylation network analysis and develop
“score and search”-based methods for exact learning causal graphs
of methylation networks to find the best-scoring structures for a
given methylation dataset. Specifically, we develop novel functional
structural equations for modeling methylation networks and use in-
teger programming to search the network with optimal score.
Results
The proposed methods were applied to AD data with 460045 CpG
sites from 748 samples. At the first stage, the methylation data of
168 gene from the pathway ‘Alzheimer’s disease were used to create
a causal network describing the connection among the methylation
sites between these genes. According to the current result, 148 gene
was matched and tested in the model. We identified a largest con-
nected causal methylation network with 47 nodes and 96 edges.
Most genes were confirmed to play an important role in the AD de-
velopment from the literature.
Conclusion
The proposed methods provide a highly flexible general framework
for causal methylation network analysis and provide more rich infor-
mation than co-methylation network. The exact learning algorithms
will guarantee to find optimal solutions and hence provide accurate
estimations of causal graphs of methylation networks. The causal
methylation networks are able to uncover the mechanism of AD
development.
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Objectives
Triple negative breast cancer (TNBC) represents a challenging tumor
type due to their poor prognosis and limited treatment options. It is
well recognize that clinical and molecular heterogeneity of TNBC is
driven in part by post-transcriptional regulators such as miRNAs. To
stratify TNBCs, we profiled 1050 miRNAs in 132 adjuvant TNBC tu-
mors and 40 tumors from other immunophenotypes using an Affy-
metrix microarray platform.
Methods
A NMF clustering analysis allowed us to identify 4 TNBC subtypes
featuring unique miRNA expression patterns, disease free and overall
survival rates and particular gene ontology enrichments. Our agglom-
erative approach was cross-validated by using two other clustering
algorithms. 3 cell line models were classified according to our miRNA
signature, recapitulating two different miRNA subgroups. The TNBC
tumors were compared against other phenotypes identifying differ-
entially expressed miRNAs to define interesting miRNAs for further
functional analysis.
Results
We found low expression levels of miR-342-3p in TNBC tumors com-
pared with other breast cancer phenotypes, and this down-regulation
characterizes one of our miRNA subgroups with high risk to re-
lapse. To characterize its functional role, miR-342-3p was transi-
ently transfected in the cell line MDA-MB-468, showing a decrease
in cell proliferation, viability and migration rates. A gene expres-
sion profile revealed 140 altered mRNAs, from which 35 are poten-
tial direct targets of miR-342-3p defined by an in-silico analysis.
The monocarboxylate transporter 1(MCT1), was confirmed as one
target of miR-342-3p by a luciferase assay and western blot analy-
sis. MCT1 repression by the miRNA promotes lactate efflux changes
in the tumor cells, reflected in the accumulation of exogenous lac-
tate and the increase in levels of extracellular endogenous lactate
together with a decrease level of intra and inter cellular glucose
concentration.
Conclusion
These data suggest a metabolic change that favors a more glycolytic
environment, which lead to a glucose deprivation context that may
contribute to the reduction in proliferation, viability and migration
capabilities already described.
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Objectives
We aim to find genes that are frequently deregulated in cancer and
thus can be useful as diagnostic markers for early detection, and po-
tentially as therapeutic targets. We focus on biomarkers with pan-
cancer potential that can be applicable to multiple cancer types.
Methods
We used the Cap Analysis of Gene Expression (CAGE) profiles of 225
cancer cell lines and 339 normal primary cells from FANTOM5 pro-
ject. CAGE is a 5′ sequence tag technology that enables promoter-
level expression analysis and can be used to estimate the activity of
enhancers from bidirectional transcription of enhancer RNAs. As a
complementary data set, we used RNA-seq data from 14 tumor
types profiled by The Cancer Genome Atlas (TCGA). In both data
sets (FANTOM5 and TCGA), we performed cancer vs. normal differ-
ential expression analysis in all cancer types.
Results
We identified a set of pan-cancer markers (of both coding and non-
coding transcripts) that are recurrently perturbed in both the can-
cer cell lines (FANTOM5) and clinical tumors (TCGA). The FANTOM5
CAGE data provided novel insights into cancer transcriptome. We
used the genomic location of the CAGE TSSs to show that pro-
moters that overlap repetitive elements (especially SINE/Alu and
LTR/ERV1 elements) are often upregulated in cancer. Specifically, a
little known repeat family, REP522 (~1.8Kb in size, largely palin-
dromic, unclassified interspersed repeat), was strongly enriched for
the most cancer-activated promoters. Here we present previously
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un-published, follow-up results that detail the REP522 activation in
cancer. Finally, we present 90 enhancers that are activated in can-
cer cell lines. With ENCODE ChIA-PET data, we linked 16 of those
enhancers to promoters of known cancer genes.
Conclusion
Our transcriptome analysis identified candidate biomarkers with pan-
cancer potential and provided new insights into enhancers and re-
petitive elements that are recurrently activated in cancer.
References
1. Kaczkowski B, et al. Transcriptome analysis of recurrently deregulated
genes across multiple cancers identifies new pan-cancer biomarkers.
Cancer Research. 2015; 76(2): 216–226.
Disclosure of interest
None declared.
O13
Elevated mutation and widespread loss of constraint at regulatory
and architectural binding sites across 11 tumour types
C. A. Semple
MRC Human Genetics Unit, MRC Institute of Genetics and Molecular
Medicine, Edinburgh, UK
Human Genomics 2016, 10(Suppl 1):O13
Objectives
Disruption of gene regulation is thought to play major roles in car-
cinogenesis and tumour progression. Here, we characterize the mu-
tational profiles of diverse transcription factor binding sites (TFBSs)
across 1,574 completely sequenced cancer genomes encompassing
11 tumour types. We assess the relative rates and impact of muta-
tion at the binding sites of 87 different transcription factors (TFs)
by comparing the abundance and patterns of single base substitu-
tions within putatively functional binding sites to matched control
sites.
Methods
To detect putatively regulatory binding sites in the genome, we used
a combination of computational prediction and experimental data.
Position weight matrices for 118 transcription factor binding motifs
were used to find TFBS motif matches in the genome. We intersected
these motif matches with experimentally defined open chromatin re-
gions to define putatively functional TFBSs. Motif matches not occur-
ring within open chromatin were used as control, putatively non-
functional sites. Comparisons between these functional and control
sites underlie our methods, and we develop novel metrics to assess
the relative rates and functional impact of cancer mutations at puta-
tively funcitonal regulatory sites.
Results
We observe a strong and significant excess of mutations at func-
tional binding sites across TFs, and show that the substitutions that
accumulate in cancers are often more disruptive than those that
are tolerated as germline variants. Putatively functional CTCF bind-
ing sites suffer an exceptionally high mutational load in cancer
relative to control sites, and those involved in the architecture of
higher order chromatin structures are the most highly mutated. The
mutational load at CTCF-binding sites appears to be dominantly de-
termined by replication timing and the mutational signature of the
tumor sample in question, suggesting that selectively neutral pro-
cesses underlie the unusual mutation patterns seen at CTCF sites
across tumor types.
Conclusion
We show that mutations at active TFBSs are common in tumours,
they appear to accumulate largely unchecked by selective pro-
cesses and are independent of mutations in coding sequences,
exhibiting distinct rates among tumor types. Our study thus under-
lines the functional importance and fragility of the regulatory gen-
ome in cancer.
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Objectives
In the U.S., the lifetime risk of developing colorectal cancer (CRC) is
4.5%. ~5% of cases carry an identified pathogenic variant in known
causal genes. In another 20%, CRC appears inherited but no known
pathogenic variant has been detected. This is partly due to lack of
evidence to classify variants as pathogenic when they occur in genes
that are implicated (GWAS, linkage, or biological pathway informa-
tion), but not proven, to be associated with CRC.
Methods
To find evidence of association for 1128 suspected CRC associated
genes, we compared the number of rare (MAF < 0.005), potentially
disruptive variants (PDV) (stop gain (SG), splice acceptor/donor
change (SA, SD), and frameshift (FS)) found in 169 CRC cases and
3524 controls. Cases included individuals from the Clinical Sequen-
cing Exploratory Research NEXT Medicine study (CSER, N=78),
Women’s Health Initiative (WHI, N=76), and Northwest Institute of
Genetic Medicine Family Polyposis Study (NWIGM, N=15). Controls
were selected randomly with respect to CRC from the Exome Se-
quencing Project (ESP), and were not known to have any Lynch asso-
ciated cancers or to carry a known pathogenic CRC variant.
Results
We found a significant association between case status and rare
PDV carrier status: 25% of CRC cases carried a rare PDV compared
to 4% of controls (p<2e-16, OR 8.1). 96 genes had 174 rare PDVs:
92 SGs, 24 SDs, 15 SAs and 43 FSs. Rare PDVs occurred in cases only
for 35 genes, in controls only for 55 genes, and in both for 6 genes.
Among cases, there were 11 SGs, 2 SDs, 6 SAs and 26 FSs. Among
controls, there were 81 SGs, 22 SDs, 9 SAs and 17 FSs. Case specific
genes had ≤2 rare PDVs: those with 2 were MKL2 and PMS1. Inter-
estingly, ATM, ATR and BRCA2 contained PDVs in both cases and
controls.
Conclusion
We show the power of aggregate information to find support for dis-
ease association in a subset of CRC implicated genes. Additionally,
we provide evidence that ATM, ATR and BRCA2 may be associated
with CRC in addition to the known association with breast cancer.
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Objectives
Next generation sequencing studies have revealed genome-wide
structural variation patterns in cancer, such as chromothripsis and
chromoplexy that do not engage a single discernable driver muta-
tion, and that currently have no clinical relevance. We aimed at a
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detailed molecular characterization of one of these genomic configu-
rations, the tandem duplicator phenotype (TDP).
Methods
We combined whole genome sequencing (WGS) data from 277 hu-
man genomes representing 11 cancer types and devised a robust
genomic metric able to identify cancers with a chromotype called
tandem duplicator phenotype (TDP) characterized by frequent and
distributed tandem duplications (TDs).
Results
Enriched only in triple negative breast, ovarian, endometrial, and liver
cancers, TDP tumors conjointly exhibit TP53-mutations, low expres-
sion of BRCA1, and increased expression of DNA replication genes
pointing at re-replication in a defective checkpoint environment as a
plausible causal mechanism. The resultant TDs in TDP augment glo-
bal oncogene expression and disrupt tumor suppressor genes. Im-
portantly the TDP strongly correlates with cisplatin sensitivity in both
triple negative breast cancer cell lines and primary patient-derived
xenografts.
Conclusion
We conclude that the TDP is a common cancer chromotype that co-
ordinately alters oncogene/tumor suppressor expression with poten-
tial as a marker for chemotherapeutic response.
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Objectives
The characterization of mRNA-expression subtypes in breast cancer
facilitates genomic and genetic studies to identify biological pro-
cesses that drive distinct molecular subtypes and elucidates the po-
tential feasibility of subtype-specific drug targets. However, such
therapies tend to have limited efficacy, often due to unpredicted
compensation in the network of mutations. Polygenic models that
account for multiple somatic mutations and their interactions can po-
tentially improve target selection and provide a more detailed view
of tumor genetic architecture.
Methods
We addressed this problem with a multi-trait genetic interaction
analysis of copy-number variation and gene expression data from
breast cancer samples in The Cancer Genome Atlas. Modules of co-
expressed genes were derived and assessed for biological function
and genetic association with mutations in oncogenes and tumor
suppressors. Summary module phenotypes with pleiotropic associ-
ated loci were simultaneously analyzed to infer direct genetic ef-
fects as well as effects mediated by genetic interactions for each
module.
Results
We observed widespread evidence of genetic redundancy, in which
two mutations combine to yield a less than additive effect that is
similar to either mutation in isolation. In addition, we also identified
interacting mutations that combinatorially associate with distinct
modules and subtypes in a non-additive manner. These somatic mu-
tant combinations were often predictive of molecular subtypes when
single mutations were not.
Conclusion
Accounting for interactions among somatic mutations in tumor samples
reveals high genetic redundancy and complex regulatory hypotheses
for breast cancer subtypes. Our work demonstrates how integrative
genetic and genomic analysis can be used to generate more precise hy-
potheses for tumor genetics, which may be used to prioritize thera-
peutic targets for robust tumor suppression.
Disclosure of interest
None declared.
O17
Recurrent somatic mutation in the MYC associated factor X in
brain tumors
H. Nikbakht1, M. Montagne2, M. Zeinieh1, A. Harutyunyan1,
M. Mcconechy1, N. Jabado3, P. Lavigne2, J. Majewski1
1Human Genetics, McGill University, Montreal, Quebec, Canada;
2Biochemistry, Sherbrooke University, Sherbrooke, Quebec, Canada;
3Pediatrics, McGill University, Montreal, Quebec, Canada
Correspondence: H. Nikbakht – Human Genetics, McGill University,
Montreal, Quebec, Canada
Human Genomics 2016, 10(Suppl 1):O17
Objectives
Activation of MYC pathway has been shown in diverse cancers. MYC
Associated Factor X (MAX) plays a key role in the MYC-MAX-MAD
gene regulatory network; however, its direct involvement in cancer
has not yet been reported. Here we report discovery of a novel recur-
rent somatic mutation in MAX in brain tumors and study its effects
on the development and progression of tumors.
Methods
We found a mutation on Arg 51 residue to Glu in MAX gene in
a patient with bilateral thalamic pediatric astrocytoma in which
the primary tumors (left and right thalamus) had nearly identical
mutation profiles except for the presence of the MAX R51Q only
in one.
We used this unique opportunity to study the effects of this muta-
tion on the progression and development of brain tumors.
We performed differential expression on these samples to find the
pathways affected by this mutation. Using ChipSeq we studied
changes in the chromatin conformation in genes regulated by this
network. We used CD experiments, to study how this mutation af-
fects the affinity between Max and other proteins in this family and
with DNA.
Results
We screened our dataset and found 7 cases in 180 HGAs exome se-
quenced by our group (3.8%) with this mutation. We also identified
14 cases in published datasets.
We found that this mutation always appears later in tumor develop-
ment in subclonal fashion and is accompanied by at least one driver
such as H3 K27M.
Our differential expression and ChipSeq experiments revealed lack of
a global effect of this mutation but specific effects on groups of
genes involved in some pathways such as apoptosis.
We also demonstrate that this mutation has no effect on the binding
efficacy between proteins in its regulatory network, but a Max R51Q
homodimer binds less efficiently to nonspecific DNA than its wild
type. It however, only affects the binding between Myc/Max hetero-
dimer to DNA in E-boxes.
Conclusion
We identify MAX as a new cancer gene, particularly relevant to brain
cancer.
Our results show the possible effects of MAX mutation in promoting
tumor progression and development. It also suggests the effect of
this mutation on the spread of the tumor.
These findings shed new light on the mechanisms underlying cancer
progression and the involvement of MYC signalling in development
of brain tumors which, in turn, can point us towards new targets for
therapeutic approaches.
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Objectives
In 2015, we demonstrated that a strong family history of BRCA re-
lated tumors portends a better prognosis in metastatic pancreatic
cancer patients. We now investigate if this holds true for more recent
patients treated with standard-of-care FOLFIRINOX (FNX) or Gemcita-
bine/nab-paclitaxel (GA). We hypothesize that targeted sequencing
of these tumors for DNA repair pathway aberrations will better pre-
dict outcomes than the surrogate marker of family history, which
may be subject to patient bias.
Methods
We identified patients with de novo stage 4 pancreatic cancer ini-
tially treated at MD Anderson Cancer Center with first-line FNX or
GA. We excluded patients with prior surgical resection (bypass was
allowed) or radiation as initial therapy, and patients with unknown
family history. Survival analysis was performed using the Kaplan-
Meier method.
Results
We identified 153 patients initially treated with FNX and 80 pa-
tients treated with GA. Median age of the entire cohort was 62
years (36–84), 58% were male. Median OS was 286 and 295 days,
respectively. Approximately 5% of patients had a family history of
3 or more BRCA tumors (breast, ovarian, prostate, pancreas). Me-
dian OS for these patients was 469 days, as compared to 285, 268,
and 296 days for patients with 0, 1, and 2 affected family members.
Median survival in patients with 3+ family members affected was
463 days and 511 days for patients on FNX and GA respectively
(95% CI 240-636d, 0–1092 d). For patients with 0–2 such family
members, median OS was 283 and 268 days, respectively. As ex-
pected, ECOG 0–1 and the absence of liver metastases were associ-
ated with longer survival. We identified 126 of 153 FNX patients
and 51 of 80 GA patients with pathology specimens available for
targeted sequencing.
Conclusion
As in our earlier report, we see a trend towards increased survival in
patients with 3 or more family members with BRCA related tumors.
However, the small number of these patients precludes a definitive
assessment. We believe that targeted sequencing of DNA repair
pathway and associated genes will better elucidate the mechanism
of survival benefit over biased family history.
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Objectives
The DDIT4 gene (DNA-damage-inducible transcript 4) encodes a pro-
tein related to adverse environmental conditions, whose action is the
inhibition of mTOR. In a recent work we found DDIT4 levels was asso-
ciated with the outcome in triple negative breast cancer (J Clin Oncol
33, 2015 (suppl; abstr 1097)). There are not previous reports relating
DDIT4 with prognosis of cancer patients. Our aim in this study was
to explore the influence of this gene in several types of malignant
tumors.
Methods
We evaluated the influence of DDIT4 expression in the outcome
(either, disease-free survival or progression-free survival or overall
survival). Univariate Cox regression analysis of DDIT4 in the online
platforms KM Plotter (http://kmplot.com/) and SurvExpress (http://
bioinformatica.mty.itesm.mx/) was done. Datasets were split based in
the median of expression. Cancer types evaluated include: Acute
Myeloid Leukemia, Brain Cancer, Breast Cancer, Bone Cancer, Cervical
Cancer, Head and Neck Cancer, Hematological Cancer, Liver Cancer,
Lung Cancer, Pancreatic Cancer, Ovarian Cancer and Prostate Cancer.
Results
A high level of DDIT4 was significantly associated with a worse out-
come in breast cancer (n=4142), P=3x10−14 (HR=1.64, CI95%: 1.44-
1.87); acute myeloid leukemia (n=168), P=3.47x10−5 (HR=2.31, CI95%:
1.55-3.43), glioblastoma multiforme (n=538), P=0.005809 (HR=1.31,
CI95%:1.08-1.59); ovarian cancer (n=1648), P=0.0096 (HR=1.2, IC95%:
1.04-1.37); head and neck squamous cell carcinoma (n=283), P=0.03347
Fig. 1 (abstract O18). Overall survival based on number of family
members with BRCA associated
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(HR=1.49, IC95%:1.03-2.15) and lung adenocarcinoma (n=866), P=0.0038
(HR=1.4, CI95%: 1.02-1.91). In contrast, a high level of DDIT4 was associ-
ated with a better prognosis in gastric cancer (n=641), P=1.7x10−6
(HR=0.62, CI95%:0.5-0.75) and lung squamous cell carcinoma (n=675),
P=0.0015 (HR=0.42, IC95%:0.24-0.73). Frequency of structural alteration
of DDIT4 found at cbioportal.org, indicate that 0 to 5.1% of primary tu-
mors where DDIT4 was related with the prognostic had mutations, how-
ever in breast tumors xenografts, gene amplification occurs in 17.4%
elucidating an key role in tumor aggressiveness.
Conclusion
DDIT4 is a promising molecular marker for outcome in several types
of cancer. In addition elucidation of DDIT4 participation in cancer ag-
gressiveness could lead to improve the therapeutic strategies, mainly
those related with mTOR inhibition.
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Objectives
The hierarchical folding of genomic DNA within the nucleus is closely re-
lated with transcriptional regulation. Recent chromosome conformation
studies have suggested that mammalian chromosomes are structured
into tissue-invariant topologically associating domains (TADs) where the
DNA within a domain is interacting more frequently than with regions in
other domains. Genes within the same TADs represent similar gene-
expression, histone-modification profiles. Therefore regions separating
different TADs (boundaries) have important roles in reinforcing the sta-
bility of these domain-wide organizations. TAD boundary disruptions in
human limb malformations and cancer lead to dysregulation of certain
genes, due to de novo promiscuous enhancer exposure to promoters.
Here we sought to identify relationship between genomic architec-
ture and genomic alterations in human cancers.
Methods
We utilized approximately 200 thousand somatic genomic alterations
(deletions, inversions, duplications) and more than 34 million somatic
mutations from 2575 high-coverage whole genome sequencing data
across 45 different cancer studies with paired normal samples. We in-
tegrated mutations, gene expression and structural alterations with
TAD boundaries that we have identified from 5 different human cell
lines, representing three different germ layers.
Results
Our analysis revealed a strong correlation between the mutational
landscape and the TAD organization of the genome. In addition, we
found that TAD boundaries inflicted structural alterations that not
only affected nearby gene regulation but also the distribution of mu-
tations in human cancers.
Conclusion
Structural alterations affecting the spatial organization of the human
genome, could lead to dysregulation of genes as well as aberrant
mutation distributions in human cancers.
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Objectives
Precision medicine initiatives in oncology focus on specific genetic
aberrations as predictive biomarkers for targeted therapies. Next-
generation sequencing technologies have driven a projectile shift in
patient management through somatic tumor profiling. Due to the
rapid pace of this ensuing momentum, it is difficult to grasp such a
dynamic landscape. Therefore, an analysis of the targeted therapy
landscape was conducted and methods employed are disseminated
to foster interoperability among datasets.
Methods
A Clinical Knowledgebase (CKB) was created to capture and rapidly re-
trieve therapeutic information related to patient molecular aberrations.
One requirement was the development of a drug class controlled vo-
cabulary to categorize drugs relative to their target specificity, including
both pan-level and more gene specific targeted drugs. Additionally, to
support capture of combination therapies, one or more single drug en-
tries can be concatenated to a therapy. Drug classes are annotated to
molecular variants and therapies are annotated to complex molecular
profiles. Using the JAX-CKB, an analysis was conducted on the number
and types of targeted therapies for solid tumors associated with 358
genes and in actively recruiting clinical trials.
Results
The CKB drug class ontology currently contains 198 terms, consisting
of 113 parent and 83 child terms. There are 1006 targeted therapies
in CKB and of these, 59 are FDA approved. Pan drug classes include
PI3K inhibitors and mTOR inhibitors, which contain 34 and 41 indi-
vidual drugs within each class, respectively. The drug class VEGFR
inhibitors (Pan) has the highest number of hits in actively recruit-
ing clinical trials, and 19 drug classes, including EZH2 inhibitor and
p53 activator, are represented in a single solid tumor clinical trial.
Furthermore, the most common drug in solid tumor clinical trials is
Bevacizumab.
Conclusion
Consistency and interoperability of knowledgebases to support cli-
nical next-generation sequencing is pivotal. The JAX-CKB, described
here, is built upon controlled vocabularies and ontologies to achieve
this mission. Methods on the design and build are shared to foster
collaborative processes in this rapidly evolving NGS domain. Further-
more, analysis of content regarding targeted therapies provides an
objective view of clinical trial research investigating targeted thera-
pies in solid tumors.
Fig. 2 (abstract O19).
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Objectives
Basal cell carcinoma of the skin (BCC) is the most common malignant
neoplasm in humans. BCC is primarily driven by aberrant activation
of the Sonic Hedgehog (Hh) pathway. However, its extensive pheno-
typical variation remains to be explained.
Methods
The genetic profiling of 293 BCCs revealed the highest mutation rate
observed in cancer (65 Mutations/Mb), with strong prevalence of UV-
light signature mutations.
Results
85% of BCCs harbored mutations in Hh pathway genes: mutually ex-
clusive PTCH1 (73%) and SMO (20%) (P=6.6x10−8), SUFU (8%), and in
TP53 (61%). 85% of BCCs also harbored additional driver mutations in
other genes implicated in BCC tumorigenesis. Recurrent driver muta-
tions were observed in MYCN (30%), PPP6C (15%), STK19 (10%),LATS1
(8%), ERBB2 (4%), PIK3CA (2%), RAC1 (1%) and N/K/H-RAS (2%). Loss
of function (LoF) and deleterious missense mutations were observed
in PTPN14 (23%), RB1 (8%) and FBXW7 (5%). In line with the muta-
tional profiles detected by DNA sequencing, we observed activation
of the Hh pathway as well as upregulation of target genes of the
Hippo-YAP pathway and activation of MYCN target genes in RNAseq
experiments.
Conclusion
The functional analysis of the novel tumorigenic driver mutations in
MYCN, PTPN14 and LATS1 demonstrates their relevance in BCC
tumorigenesis and provides an expanded molecular understanding
of BCC.
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Objectives
Hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA) are
the members of hepato-biliary diseases. As both HCC and CCA arise
from similar cell types, they often exert high levels of similarity in
terms of phenotypic characteristics, thus leading to difficulties in
HCC and CCA differential diagnoses. In this study, a meta-analysis
was performed on HCC and CCA transcriptome microarray data for
the purpose of investigating differential transcriptome networks and
potential biomarkers of CCA and HCC.
Methods
Raw data from 9 HCC and CCA gene expression microarray datasets,
consisting 1,185 samples in total, were methodologically compiled
and analyzed. For determining differentially-expressed genes in the
cancers, gene expression were compared between cancer and its re-
spective normal samples (HCC vs Normal Liver and CCA vs Normal
Bile Duct) using t-test and k-fold validation (P < 0.05).
Results
Comparing to normal samples, 226 differentially-expressed genes
were specifically observed in HCC, 249 genes in CCA, and 41 genes
in both. Gene Ontology and KEGG pathway enrichment analyses
showed different patterns between functional transcriptome net-
works of HCC and CCA. Cell cycle and glycolysis/gluconeogenesis
pathways were specifically affected in HCC whereas complement and
coagulation cascades as well as glycine, serine and threonine metab-
olism were predominantly presented in CCA.
Conclusion
Our meta-analysis revealed different dysregulation in transcriptome
networks between HCC and CCA. Some genes in these networks
were selectively discussed in the context of HCC-CCA transition, unique
characteristics of HCC and CCA, and their potentiality as HCC/CCA dif-
ferential biomarkers.
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Objectives
Clinical genetic testing is rapidly evolving with the introduction of
next-generation sequencing (NGS) however questions remain about
these new tests. First, can NGS methods be deployed that deliver
equal or improved performance vs. traditional methods on the full
spectrum of (often complex) disease causing variants? Second, do ex-
panded NGS tests provide medical benefits which outweigh the in-
creased uncertainty that naturally follows from testing more genes in
more patients? In recently published work [1,2] we tested a large
panel of cancer risk genes by NGS in a clinically representative popu-
lation to evaluate these questions. Here we expand upon that work
with additional cases including patients with expanded indications
for testing and complex presentations.
Methods
We tested a large panel of 25–32 cancer risk genes by NGS in a rep-
resentative cohort of over 1000 patients meeting current medical
guidelines for BRCA1/2 testing. Traditional genetic test results were
available for the patients for comparison. Using an interpretation sys-
tem (Sherloc) based on ACMG 2015 guidelines and employing only
publicly available data, variants uncovered by NGS were classified.
We established a uniform algorithm based on current practice guide-
lines to recommend management actions for the non-BRCA1/2 posi-
tive individuals, and we evaluated which of these recommendations
would represent changes in management above and beyond any
recommendations based on personal and family history alone.
Results
We find 100% concordance with traditional methods on both sequence
and copy-number alterations using a battery of 5 calling algorithms
and associated biochemistries., we find 99.8% concordance with
BRCA1/2 classifications produced by a different laboratory that uses a
large proprietary database. Finally, we find that 52% of genetic test re-
sults positive for genes other than BRCA1/2 would warrant consider-
ation of a change in care for mutation-positive patients under current
medical practice guidelines.
Conclusion
In appropriately referred patients, multi-gene panel testing yields
clinically relevant findings with potential management impact for
substantially more patients than does BRCA1/2 testing alone.
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Objectives
Neuroblastoma, the most common extra-cranial solid tumor in the
pediatric population, is a histologically and clinically heterogeneous
neoplasm. Tumors characterized only by whole chromosome changes
tend to act favorably, whereas tumors with MYCN gene amplification
and/or segmental chromosomal aberrations have poor outcomes.
Given the clinical relevance, our aim was to verify the accuracy of
OncoScan FFPE SNP Array (Affymetrix) in assessing genome-wide copy
number changes in tumor samples by comparison to other tumor
ploidy testing methods.
Methods
39 neuroblastic tumors from 38 patients were analyzed using the
OncoScan FFPE SNP Array at a pediatric hospital. Tumor slides were
macrodissected to increase tumor purity, genomic DNA was isolated
and arrays hybridized according to manufacturer’s protocol. Data was
analyzed using the OncoScan Console and results viewed using
Chromosome Analysis Suite (ChAS) and OncoScan Nexus Express.
Copy number results determined by SNP array were compared to
ploidy results obtained by karyotype analysis and/or flow cytometry.
Additionally, chromosome 1 and 2 aneuploidy data were used as a
surrogate ploidy marker in cases where cytogenetics and flow cytom-
etry were unavailable.
Results
Data were obtained for 33 of the 39 samples. Review showed that 3
of the 33 samples required recentering of the tumor ploidy baseline.
Two samples from 2 lesions in one patient showed widely discordant
copy number calls by the software, with one assigned a near tetra-
ploid status and the other a near diploid status. Karyotype analysis
confirmed a near tetraploid state. Correlation by karyotype, flow cy-
tometry or chromosome 1 and 2 aneuploidy revealed an additional 4
discordant cases (total of 5/33 cases or 15%).
Fig. 4 (abstract O23).
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Conclusion
Despite complex algorithms used by the OncoScan software to as-
sign copy number calls, in 15% of the analyzed cases a 2nd method
was necessary to correctly assign tumor ploidy baseline. The complex
chromosomal copy number changes present in tumors, in addition
to tumor impurity, heterogeneity, and poor sample quality, can chal-
lenge the software’s ability to correctly assign ploidy state. Our
results demonstrate that a second independent method may be ne-
cessary in complex tumor cases to correctly assign ploidy that truly
reflects tumor biology and that may be necessary for correct patient
management.
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Objectives
Structurally complex loci underlie many diseases. These loci can be
very challenging to resolve by currently available methods such as
karyotyping, clinical array, PCR-based tests, and NGS. Next-generation
mapping by BioNano Genomics Irys® System offers a high-throughput,
genome-wide method able to interrogate genome structural differ-
ences hundreds of kilobase pairs and span interspersed and even
long tandem repeats making it ideally suitable for elucidating the
structure and copy number of complex regions of the genome,
such as complex pseudogene and paralogous gene families. Clinic-
ally relevant regions often contain genes with paralogs and other
complex repetitive structures complicating the interpretation of
data and diagnosis of disease. We present several examples of gen-
etic loci that can be easily interrogated with genome map data in-
cluding tandem repeats, paralogous gene families, and loci flanked
by segmental duplications.
Methods
Some open reading frames or entire genes are randomly amplified
with variable copy number such as tRNAs, kringle IV, and D4Z4. The
LPA gene contains variable copies of a repeat, kringle IV, that results
in different lengths of the resultant Lp(a) protein; related to coronary
heart disease, cerebrovascular disease, atherosclerosis, thrombosis,
and stroke. Tandem repeat is D4Z4, associated with facioscapulo-
humeral muscular dystrophy (FSHD), with a low copy number (<10
units), occurring in 95% of FSHD cases.
Results
We show that the Irys System can accurately measure the copy
number of the kringle IV domain and D4Z4. A second class of com-
plex structural variation are those that involve genes with paralogs
such as amylase and UGT2B17, two genes whose copy number have
been shown to be involved in human health. We show deletions of
UGT2B17 in a family trio and > 10 different structures at the Amyl-
ase region. The third class of genomic variation are those flanked
by segmental duplications, especially important because spontan-
eous rearrangements are common between paralogous segmental
duplications causing copy number aberrations and translocation,
thus resulting in developmental disorders, such as the 22q11.2 deletion
syndrome mediated by segmental duplication rearrangements.
Conclusion
We show the assembly of the region, including the normal and
pathogenic alleles, using molecules that span and disambiguate the
structure of the segmental duplications.
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Objectives
To identify the genetic determinants of Pulmonary Arterial Hyperten-
sion (PAH) in a cohort of pediatric PAH patients.
Methods
We performed whole-exome sequencing (WES) in a cohort of 60 pro-
bands with PAH and family members when available (180 total indi-
viduals) without a molecular diagnosis after most of the series was
screened for mutations in BMPR2. In addition, we performed WES in
additional 118 singleton cases. We screened all samples for variants
in known PAH associated genes and performed trio-based analysis to
identify novel candidate PAH genes.
Results
We identified known and novel mutations in the known PAH genes.
In addition we identified novel truncating variants in TBX4 occurring
de novo or inherited from an asymptomatic parent in 5 patients and
a de novo predicted deleterious nonsynonymous variant in one add-
itional patient.
TBX4 is a transcription factor of the T-box gene family. It is expressed
in a variety of tissues during early mouse development including the
atrium of the heart, the limbs, and the mesenchyme of the lung and
trachea. TBX4, jointly with TBX5, has been shown to interact with
FGF10 during lung growth and branching. Mutations in TBX4 have been
previously reported to cause small patella syndrome, an autosomal-
dominant skeletal dysplasia characterized by patellar aplasia or hypo-
plasia. A study in 2012 [1] identified an association of TBX4 mutations
with PAH in 6 patients.
Conclusion
We identified 6 different deleterious variants in TBX4 (2 inherited and
5 de novo) in our initial cohort of trios where patients were as-
certained for primary pulmonary arterial hypertension, accounting
for ~10% of the probands in this series. Subsequently we confirmed
this association in additional 4 singleton cases, including a patient
with a large intragenic microdeletion of TBX4. Our results confirm
the role of TBX4 as an important cause of hereditary PAH, account-
ing for ~5% of our whole PAH cohort.
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Objectives
To identify mutations causing North Carolina macular dystrophy
(NCMD, MCDR1).
Methods
We performed targeted Nex Gen sequencing of the MCDR1 region
(870kb) in 8 affected individuals from 3 families representing 3 differ-
ent haplotypes affected with chromosome 6 linked NCMD (MCDR1).
In addition to our original 11 MCDR1 families recently published (141
total subjects), we now have an additional cohort of 23 families with
the NCMD phenotype available for study (total of 367 subjects, 32
families).
Results
We initially found 14 rare variants spanning 870kb of the disease-
causing allele. One of these variants (V1, ch6:1000400906) was absent
from all published databases and all 261 controls, but was found in a
total of 13 NCMD kindreds. This variant lies in a DNase 1 hypersensi-
tivity site (DHS) upstream of both the PRDM13 and CCNC genes.
Sanger sequencing of 1 kb centered on V1 was performed in the
remaining NCMD probands, and 2 additional novel single nucleotide
variants (V2, ch6:10000987, in 6 families and V3, ch6:100041040 in 1
family) were identified in the DHS within 134 bp of the location of
V1. A complete duplication of the PRDM13 gene was also discovered
in a single family (V4). The 4 mutations V1 to V4 segregated perfectly
in the 118 affected and 33 unaffected members of the 21 NCMD
families.
Conclusion
We identified 4 rare mutations in a non-coding region, each capable
of arresting human macular development by causing over expression
of PRDM13. Additional families with the NCMD phenotype continue
to support that these mutations are causative of MCDR1 / NCMD.
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Objectives
To identify the causative variant(s) and gene(s) of rare Mendelian
phenotypes by the re-analysis of unsolved whole exome sequecing
(WES) data.
Methods
To address some of these cases, we have incorporated maternal and
paternal imprinting analysis and polygenic analysis to the PhenoDB
Variant Analysis tool. We also analyzed WES data from 1063 samples
for rare, functional variants in known imprinted genes, in the genes
on pseudoautosomal regions, genes that escape X-inactivation, and
genes on chromosome Y. To facilitate data sharing as well as im-
prove the search for patients or model organisms with variants in
specific candidate genes we have also been adding capabilities to
GeneMatcher (www.genematcher.org). In GeneMatcher there is an
option to match based upon OMIM® number, genomic location and,
as of October 2015, on phenotypic features. As part of the Match-
maker Exchange (MME) (http://matchmakerexchange.org/), we have
also developed an API that was implemented in August 2015 and al-
lows the GeneMatcher users to submit their data to query Phenome-
Central and/or DECIPHER. Also, as part of the MME we have been
working with other matchmaker databases on the API implementa-
tion to connect them to GeneMatcher and have been working on
the version 2.0 of the API that will allow for more detailed queries.
Results
We found that the genes in the pseudoautosomal regions are not
captured by the Agilent SureSelect v4 baits that we used to se-
quence these samples. The analysis of variants in the genes on
chromosome Y identified 52 rare functional variants and the analysis
of variants in the 242 imprinted genes identified 4,337 rare functional
variants. These variants are being further evaluated to define causal-
ity. As of December 2015, 3,568 genes were submitted to Gene-
Matcher by 984 individuals from 48 countries and 1252 matches (60
matches with PhenomeCentral and 34 matches with DECIPHER).
Conclusion
The GeneMatcher approach has enabled collaborations and the de-
scription of novel Mendelian phenotypes and novel Mendelian genes
like SPATA5, HNRNPK and TELO2. We expect that further use of Gene-
Matcher and other MME matchmaker databases will enable many
new gene/phenotype connections and that the full impact this ap-
proach will be revealed in the published literature over the next
years.
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Objectives
At its inception in 2011 the Baylor-Johns Hopkins Center for Mendel-
ian Genomics (BHCMG), as one of three NIH funded Centers for Men-
delian Genomics (CMGs), began its efforts towards: i) novel gene/
mutation discovery, ii) elucidating the molecular bases of disease, iii)
understanding the genetic susceptibility to disease traits, and iv) de-
termining the genetic/genomic architecture of disease. Collectively
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the CMGs have sequenced ~19,000 patient samples in collaboration
with more than 500 investigators from 36 countries in the past four
years. The BHCMG has learned many lessons from its contribution
of 5,200 exomes ranging in 475 phenotypes and presented in 82
publications.
Methods
The Human Genome Sequencing Center (HGSC) at the Baylor College
of Medicine has generated 46 TB of whole exome sequencing
(WES) data using the HGSC-VCRome capture reagent and now in-
cludes ‘Spike-in PKv2’ to capture more difficult regions and add-
itional gene targets. The HGSC-VCRome capture reagent, along
with a multiplex strategy and use of full-length blocking oligos
employed for hybridization, has yielded 7.7Gb of data per exome
providing a coverage of 96% at 20X or greater. The Spike-in PKv2
reagent is comprised of 3,643 additional unique gene targets de-
rived from GeneTests, OMIM, selected cancer genes and Baylor
Miraca Genetics Laboratory positive cases. The addition of this re-
agent converts >700-800 genes from partially covered to fully cov-
ered at ≥ 20X coverage.
Results
Success rates in this program have varied by phenotype and cohort
collections ranging from 37% to 85%. The BHCMG has established
valuable sample acquisition approaches and resources, enhanced se-
quencing methodology, curated a well-characterized phenotype-rich
genetic database enabling genotype/phenotype relationships and
encouraged collaborative efforts (i.e. GeneMatcher) to implicate 491
disease genes including 192 novel, 152 known and 147 phenotypic
expansion genes.
Conclusion
Each discovery has shown the diagnostic capabilities in using WES
and has taught lessons in disease mechanisms that continue to drive
investigation into those cases that remain unsolved.
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Objectives
Accurately identifying genetic differences between individuals or
within samples taken from the same individual (tumor with normal
control) is important to understanding the etiology of diseases, par-
ticularly for disease areas where large structural changes in the gen-
ome have been associated with the disease, such as neurological
conditions, cardiological conditions and cancer. In clinical practice,
identifying a previously uncharacterized de novo SV in an offspring
that could be causing a condition is challenging with current
methods that often have high false discovery rates.
Methods
Here, we present Biograph Anchored Assembly (BAA), an SV caller
using whole read overlap assembly of reads that do match the refer-
ence exactly. In a previous study with next-generation sequencing of
the reference individual HS1011 (English et al. (2015)), the method
has been shown to have high sensitivity compared to other SV cal-
lers and a false discovery rate of less than 5%. The method is based
upon the BioGraph data storage format (BAF). The BAF is a special-
ized index of the read overlap graph of a genome that can be quer-
ied up to one million times a second. Querying by both coordinate
and sequence is particularly applicable to SV typing.
Results
Using BAA on a trio sequenced by the Personal Genome Project
(PGP), the BAA variant caller detected a 3.4kb insertion inherited in
the offspring that matched an alternate allele assembly now in
GRCh38. The breakpoint and sequence of the insertion were reported.
The resolution of this inserted sequence allowed for five SNPs and an
indel that were inherited from the father and a single SNP inherited
from the mother to be distinguished in the offspring.
Conclusion
This level of resolution and accuracy in calling allows for structural
variants, and even differences between structural variants, to be
compared across individuals. This is important both for understand-
ing the etiology of disease in larger studies as well as identifying de
novo variants in an offspring in a clinical setting. Here, we further
present results from 100 HiSeq X samples sequenced at 30x, includ-
ing multiple classes of structural variants and multi-sample classifica-
tion of shared breakpoints.
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Objectives
The successful translation of genomic discovery into improvements
in human health hinges on the effective and responsible sharing of
genomic and health related data. The Global Alliance for Genomics
and Health (GA4GH) brings together over 375 leading healthcare,
research, disease advocacy, life science, and information technol-
ogy organizations committed to establishing harmonized approa-
ches to data sharing. The Regulatory and Ethics Working Group
(REWG) of the GA4GH specifically promotes the legal interoperability
of data.
Methods
The REWG establishes Task Teams with diverse, international mem-
bership across sectors to develop tools and solutions to facilitate
data sharing. Existing Task Teams address Consent, Privacy & Secur-
ity, Accountability, Paediatrics, Ageing and Dementia, Registered Ac-
cess, Participant Values, and Machine Readable Consent.
Results
The REWG has developed a Framework for Responsible Sharing of
Genomic and Health-Related Data, which aims to activate the human
right of every citizen to benefit from the progress of science. This hu-
man rights basis gives the Framework political and legal dimensions
that reach beyond the moral appeals of bioethics. Specific policies
build on the Framework. The Consent policy provides guidance for
balancing individual autonomy with the public good, and addresses
sharing of legacy data where consent is silent on data sharing. The
Privacy and Security policy emphasizes that safeguards should be
proportionate to the risk of harm to patients. The new Accountability
Policy provides best practices for transparency of data handling, as
well as processes for monitoring and responding to non-compliance
with data sharing standards.
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Conclusion
In addition to these policies, ongoing initiatives within the REWG
are tackling a host of related questions. What language is appropri-
ate for consent to broad data sharing? Is there a middle ground be-
tween open and controlled access? Can conditions of data access
be rendered machine readable, so as to enable automated data
discovery? Can researchers be held accountable for not sharing
data where patients have consented to broad sharing? And how
do patients and the public feel about sharing their data for broad
research purposes?
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Objectives
Short interspersed elements B2 (SINE B2) are broadly distributed
transposable elements in whole mouse genome. Evolutionally, SINE
B2s share common ancestors with tRNAs. Among the various remark-
able functions of recently discovered non-coding RNA functions, we
discovered a new class of antisense non-coding RNAs (SINEUPs) that
promote translation of partially overlapping sense coding mRNAs
with no effects on RNA levels.. In order to develop synthetic SINEUPs
to up-regulate therapeutically interesting genes, we have determined
that SINEUPs function requires two essential domains; one is SINE B2
element, also called the Effector Domain (ED), and the other is over-
lapping antisense RNA sequence, which provide specificity and is
called the Binding Domain (BD). We have produced functional SINE-
UPs for to a PD associate gene, PARK7 (DJ-1), as well as other genes.
This synthetic SINEUP specifically enhances translation level of PARK7
mRNAs in human neuronal cell lines. Through a novel high-throughput
screening (HTS) system, we aim at further optimization of the ED and
BD of SINEUPs to produce very effective SINEUPs against any possible
mammalian protein.
Methods
We report here our HTS, which is based on high-resolution auto-
mated fluorescent imaging of CeligoS instrument. We screened with
the HTS several BDs for a hepatic transcription factor alpha (Hnf4-
alpha), which is associated to maturity-onset diabetes of the young
type 1.
Results
In addition, we validated that several SINEUPs targeting Hnf4-alpha are
able to upregulate translation in mouse hepatoma cells and hepatocyte
cells. We also validated that other EDs derived from natural SINE B2 se-
quences revealed target mRNA specific translation enhancement.
Conclusion
To conclude, synthetic SINEUPs are promising tools for gene/RNA
therapy of haploinsufficiencies, and the HTS system is a powerful
SINEUPs screening platform.
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Objectives
Rare and undiagnosed disorders challenge patients, families, and cli-
nicians. In 2008, NIH started an Undiagnosed Diseases Program
(UDP), with the goals of providing answers to patients with mysteri-
ous conditions that eluded diagnosis and advancing medical know-
ledge about diseases. The UDP has expanded in the US, as the
Undiagnosed Diseases Network, with 6 additional clinical sites, a co-
ordinating center, 2 DNA sequencing cores, a model organisms
screening center, a metabolomics core, and a biorepository. For fur-
ther expansion, meetings were held in Rome and Budapest with clin-
ician scientists from 7 nations.
Methods
The plan includes launching the UDNI (Australia, Canada, Hungary, Italy,
Japan, Sweden, and the United States). The goals are to improve the
level of diagnoses and care for such patients by common protocols, to
facilitate research in disease etiology, and to create a collaborative re-
search community. A comprehensive “–omics” approach would include
exomic and genomic sequencing as well as metabolomics. The interim
website is http://test.areasrl.com/udni/home.
Results
To date, several principles are being implemented: Engaging centers
of excellence, fostering a collaborative research environment, estab-
lishing a cooperative governance structure, designing a common re-
search protocol, providing a uniform patient experience, collecting
data by recognized standards, protecting patient data, observing eth-
ical, legal, and social guidelines, devising broad data sharing, sti-
mulating dissemination of results, and ensuring a well-functioning
network. A Board of Directors integrates working committees, includ-
ing Patient Advocacy, Clinical Management, Sequencing, Databases,
and Repositories.
Conclusion
Further meetings should consolidate support and logistics. Details
are available (Taruscio E, et al., Undiagnosed Diseases Network Inter-
national (UDNI): White Paper for Global Actions to Meet Patient
Needs (Mol Genet Metabol, in press).
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Objectives
Several computational methods have been developed to predict
whether amino acid substitutions result in disease. This type of analysis
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is included in the ACMG/AMP guidelines for pathogenicity classification
of variants and is being used by the Clinical Genomics (ClinGen) re-
source. These methods are generally blind to the underlying disease
mechanism. Little is known about how mechanism of disease affects
the predictive ability of these algorithms for variants implicated in
inherited diseases. We address this by focusing on two classes of genes
that differ in their molecular mechanism of action. Activating/gain-of-
function mutations in oncogenes and loss-of-function mutations in
tumor-sppressor genes(TSG) are pathogenic in cancer development.
Moreover, unlike TSG, oncogenes are recurrently mutated at several
amino acid positions.
Methods
We obtained 5078 missense variants in 29 oncogenes and 50 TSG,
classified based on their pattern of mutations in COSMIC(1), from the
ClinVar database and annotated them with 20 computational algo-
rithms. These variants had clinical assertions provided by the submit-
ting laboratory. We analyzed variants classified as either pathogenic
or benign in oncogenes (n=321) and TSG (n=832).
Results
We found less concordance among the algorithms assessed for patho-
genic variant prediction in either class of genes. Also the set of algo-
rithms that were concordant in predicting benign and pathogenic
variants differed on whether the variant was an oncogene or TSG. The
concordant (e.g. GERP++) algorithms are primarily based on evolution-
ary conservation. A combination of GERP++ and the functional predic-
tion algorithm FATHMM is more likely to produce discordant results for
oncogenes. This implies that curators choosing different sets of compu-
tational algorithm are likely to result in different inferences for the same
variants. We are developing statistical approaches to identify algorithms
that produces maximal separation of benign and pathogenic variants
for oncogenes and TSGs and applying them in a larger set of variants
in the list of 56 genes recommended for reporting for incidental find-
ings differing in their disease mechanism.
Conclusion
We find evidence that disease mechanism needs to be taken into
consideration when deciding on algorithms for predicting pathogen-
icity. Our findings may aid in further classification of variants of un-
certain significance.
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Objectives
The Baylor College of Medicine’s Human Genome Sequencing Center
and the Mayo Clinic’s Center for Individualized Medicine are collabora-
tively working to sequence up to 10,000 patients from the Mayo Clinic
Biobank. The objective of these efforts is to incorporate the results in
patient electronic health records (EHRs) thus guiding clinical drug pre-
scribing practices in terms of efficacy and avoidance of adverse events.
Methods
This study takes a prospective approach using a combination of re-
agents including a targeted panel of seventy-six pharmacogenomically
relevant genes developed as part of the Pharmacogenomic Research
Network (PGRN). Specific targets are based primarily on a combination
of community feedback and clinical guidelines published by the PGRN’s
Clinical Pharmacogenetics Implementation Consortium (CPIC). The tar-
gets include both gene coding regions and SNP targets aimed at char-
acterizing both known and novel variants while keeping the costs
equal to or below microarray-based genotyping approaches.
Results
Preliminary data was generated using 500 samples used previously
as part of the Mayo Clinic’s eMERGE Network studies. Each institu-
tion developed both data generation and analysis pipelines geared
toward identification of genomic variants and haplotypes influen-
cing commonly prescribed drug efficacies and toxicities. Prelimin-
ary sequencing data quality was outstanding and demonstrated
high variant correlation with the previous dataset. Improvements
in haplotype calling and clinical decision support are ongoing.
Moving forward, the Mayo Clinic’s Center for the Science of Health
Care Delivery will be tracking outcomes to confirm the value of
this approach.
Conclusion
In conclusion, this study will provide a large cohort blueprint for
implementation of pharmacogenomics in precision individualized
health care.
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Objectives
Targeting immune checkpoints has proven to be an effective strat-
egy for the treatment of metastatic melanomas. However, less than
half of patients respond to the immune checkpoint blockade. A
complete understanding of molecular mechanisms underlying tumor
response is lacking. In this study, we propose that the degree of mel-
anoma cell “re-programming” may contribute to melanoma tumor re-
sistance to immune therapy.
Methods
We employ RNA-sequencing (RNA-seq) and Reverse Phase Protein
Array (RPPA) data from 68 early passage melanoma cell lines derived
from tumor infiltrating lymphocyte harvests of 63 patients to identify
biological processes and marker genes underlying the melanocyte
“re-programming”. We propose a scoring system of the process
based and employ it to study effects of the re-programming on out-
comes of the immune therapy using a transcriptomics dataset (Van
Allen et all, 2015) from pretreatment metastatic melanoma tumor
samples from patients treated with ipilimumab (anti-CTLA-4).
Results
Melanoma cells grouped into 3 major concordant clusters by both
RNA-seq and RPPA analysis (Fig. 5). Examination of the genes under-
lying the clustering revealed profound differences in the expression
of genes associated with melanocyte differentiation (including MITF)
and with the Epithelial to Mesenchymal Transition (EMT) process. We
determined the mean Z value for genes within each process, and
designated the difference between the mean expressions as the “re-
programming score” (RPS). Using the same set of marker genes for
melanoma tumor samples we significantly separated responders
from non-responders of the immune therapy and revealed 2 groups
of non-responding tumors. Each group had a different subset of
highly expressed EMT-associated genes, and opposite expression of
the differentiation-associated genes. Combining a subset of genes that
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are differentially expressed between responders and non-responders
we markedly enhanced the prognostic value of the cytolytic score, a
known prognostic feature.
Conclusion
The proposed scoring system of the melanocyte re-programming
based on the RPS may hold prognostic value for immunotherapy
treatments outcomes.
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Objectives
Challenges in research, diagnosis and treatment of complex disease
emerge from the poor alignment of the underlying biology of disease
with a nosology defined by externally manifest signs and symptoms.
Aggregate functional genomics data can enable the development of a
data driven nosology in which disease characteristics, research models,
diagnostic categories and drugs are more precisely aligned to specific,
biologically based facets of disease.
Methods
GeneWeaver consists of a database and analysis tools for aggrega-
tion of heterogeneous functional genomics data across species, in-
cluding curated pathways, ontology annotations, publication data,
genetic mapping, transcriptome and proteome experiments, and
other functional genomics data including user-submitted experimen-
tal results. Each is described with meta-content, enabling retrieval by
disease related terms. Gene identifiers are harmonized to enable ag-
gregation of data through homologous genes and gene products. To
evaluate specificity of disease descriptors, we analyzed intersections
among gene sets associated with disease-related terms. These gene
sets were derived from studies of nine different organisms and con-
sisted of genome-wide experiments, curated annotations to ontology
terms and genes associated to disease-related terms through transi-
tive association of genes, publications and MeSH terms.
Results
Analyses of term-to-term associations reveals that genes associated
to co-occurring or difficult to discern diseases exhibit weak overlap
across many different terms, especially those associated with psychi-
atric disorders which display extensive cross-disorder overlap. In con-
trast, more well-bounded disorders, such as degenerative ocular
disorders, reveal strong and specific overlap and good matching of
empirically derived data sets and annotations. By enumerating all
intersecting associations of genes to disorders, we are simultaneously
able to identify genes that differentiate among overlapping disor-
ders, potentially defining the specific and unique aspects of these
conditions for precise differentiation of disease.
Conclusion
The integration of heterogeneous functional genomics data provides
insight into the latent biological basis underlying the organization of
heterogeneous disease.
Supported by NIH AA18776, jointly funded by NIAAA and NIDA.
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Objectives
How to efficiently extract biomarkers for risk prediction and treat-
ment selection from millions or dozens of millions of genomic vari-
ants raises a great challenge. Traditional paradigms for identifying
variants of clinical validity are to test association of the variants. How-
ever, significantly associated genetic variants may or may not be
efficient for diagnosis and prognosis of diseases. Alternative to
association studies for finding genetic variants of predictive utility
is to systematically search variants that contain sufficient informa-
tion for phenotype prediction.
Methods
To achieve the goal, we introduce concepts of sufficient dimension
reduction (SDR) which project the original high dimensional data to
very low dimensional space while preserving all information on re-
sponse phenotypes. We then formulate a clinically significant genetic
variant discovery problem into the sparse SDR and optimal scoring
problem and develop algorithms that can select significant genetic
variants from high dimensional data. To speed up computation, we
apply the alternating direction method of multipliers to solving the
sparse optimal scoring problem which can easily be implemented in
parallel.
Results
To illustrate its application, the proposed method is applied to a cor-
onary artery disease (CAD) dataset from the Wellcome Trust Case
Control Consortium (WTCCC) study, Rheumatoid Arthritis (RA) dataset
from the GWAS of North American Rheumatoid Arthritis Consortium
(NARAC) and the early-onset myocardial infarction (EOMI) exome se-
quence datasets which have European origin from the NHLBI’s Ex-
ome Sequencing Project. To evaluate the performance of the SDR for
disease risk prediction, we present Table 1 that lists AUC of our SDR
and other 10 existing methods. Table 1 clearly demonstrated that
our proposed SDR method has much larger AUC than other 10 exist-
ing methods.
Conclusion
We shift the paradigm of feature selection from P-value and risk
score ranking to optimal genome-wide searching. The SDR-based op-
timal genome-wide searching methods substantially outperform other
existing methods for disease risk prediction. Our results strongly dem-
onstrate that the rich genetic variation information provides powerful
resources for disease risk prediction.
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Objectives
Next generation genomic and image technologies produce a deluge
of DNA sequencing, transcriptomes, metabolic, image, physiological
phenotypes with millions of features. Analysis of increasingly larger
and more complex data gives scientists access to vast amounts of in-
formation that was previously unavailable, but also poses great
methodological and computational challenges. This talk provides
perspectives for paradigm changes in current public health data
analysis.
Methods
We develop novel statistical methods for paradigm changes in big
genomic, epigenomic and imaging data analysis from low dimen-
sional data to high dimensional data analysis. We develop novel
functional structural equations with integer programming as a new
framework for inferring large-scale causal networks of genomic-
images and detecting pleiotropic effects of genetic variants on im-
aging. In addition, we develop new causal machine learning methods
for network classification and combine images and genomic data for
disease risk prediction.
Results
The proposed method for large-scale genomic-imaging causal net-
work analysis was applied to the MIND clinical imaging consortium’s
schizophrenia image-genetic study with 142 diffusion tensor images
(DTI) with 538265 voxels and 14,412 genes in 64 schizophrenia pa-
tients and 78 controls. Each DTI were segmented into 41 regions.
The causal image-genotype networks were constructed for all the in-
dividuals. In cases, the image network consisted of 41 nodes and 68
edges, and in controls, the image network consisted of 41 nodes and
65 edges. We identified 1,035 and 1,618 genes that were significantly
connected to the image regions respectively. 27 genes in cases and
40 genes in controls were in the 108 schizophrenia associated gen-
etic loci. The developed network classification algorithm was also ap-
plied to predict schizophrenia. Using cross validation, we can achieve
100% prediction accuracy in the training data and the average pre-
diction accuracy, sensitivity and specificity in the test data were
95.1%, 96.2% and 93.9% respectively.
Conclusion
We shift the paradigm of big genomic and imaging data analysis
from association studies to causal inference and provide powerful
tools for unravelling causal chain of mechanisms of psychiatric disor-
ders, delivering new therapeutic targets and biomarkers for precision
medicine
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Objectives
In the wake of the development of new Next Generation Sequencing
(NGS) instruments and methodologies, genetic research has become
more prominent during the past several years. However, many la-
boratories and institutions still face significant issues in their modus
operandi: Storage, processing, and sharing of NGS data and results.
We propose a novel approach to overcome mentioned issues: Wiki-
nome, a cloud based platform specifically designed and developed
to deal with the issues typical bioinformatics laboratories are con-
fronted with, allowing faster and more efficient ways to conduct NGS
data analysis.
Methods
Wikinome allows its users to store, manipulate, analyze and share
their data and results from anywhere, using desktop computers, lap-
tops, or even mobile devices, without the need of maintaining a high
powered computer in the lab. Once the NGS data are uploaded, it
can be analyzed using various pipelines that can be planned and ex-
ecuted using any of Wikinome’s clients. Utilizing a Service oriented
Architecture (WCF), all steps of an analysis workflow are called indi-
vidually to perform the underlying analysis process, such as reads-
mapping, reads-clustering, or performing a BLAST search. Access-
controlled files in a Big Data Storage environment allow users to
share data with collaborators at the ease of a button click, instead of
physically or digitally moving data.
Results
We have successfully implemented a platform allowing all people
and institutions that conduct genetic sequence analysis, to com-
pletely move their analysis procedures into the cloud, independent
from the sequencing instruments that were used to produce the
NGS data. Utilizing standard modules such as quality control, reference-
mapping, gene-detection, de-novo assembly, alignment, and BLAST,
Wikinome not only allows users to define custom analysis workflows;
users can even add services hosted inside their own labs, without the
need of exposing them in the cloud. Instead of working with
command-line based algorithms and tools, users are automatically noti-
fied upon finishing certain procedures of the currently running work-
flow, and have access to live updates. Users can also add their own
custom analysis modules and share them with collaborators within the
Wikinome network.
Conclusion
With Wikinome, we have successfully developed a solution to per-
form analysis on NGS data on a previously unthinkable scale with the
potential to overcome many of the typical Big Data issues in the field
of genetic research and analysis.
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Objectives
Efforts to move high throughput sequencing into the clinic must
confront many challenges including meeting clinical standards for
cost, reproducibility, quality, ethical and privacy considerations. The
Melbourne Genomics Health Alliance was formed from a diverse
group of institutions with the aim of sharing the burden of these
challenges through a common sequencing and bioinformatics plat-
form. In this work, we present a shared, open source analysis pipeline
that was developed to meet these needs.
Methods
To enable a single solution for many different diseases and laborator-
ies, we employed the Bpipe pipeline platform which allows for ana-
lysis stages to be easily added, substituted, replaced or customized
on a per-sample or per-disease basis. Bpipe also offers powerful
Table 1 (abstract O40)
Dis-
ease
BLUP GRC BSLMM Multi-
BLUP
Elastic
Net
Lasso Dis-
ease
BLUP GRC BSLMM Multi-
BLUP
CAD 0.58 0.57 0.59 0.59 0.683 0.678 CAD 0.58 0.57 0.59 0.59
RA 0.61 0.67 0.69 0.73 0.765 0.766 RA 0.61 0.67 0.69 0.73
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features for parallelization, so that pipelines can easily run on differ-
ent distributed clusters or on dedicated computing resources. To en-
sure that the solution can be freely shared, it is released under the
GPLv3 open source license.
Results
We have developed Cpipe, a shared, open source sequencing pipe-
line designed for clinical users. Cpipe includes support for the full
range of features required in real world clinical sequencing applica-
tions. It allows for customized sets of targeted regions, prioritized
genes, screening of incidental findings, automatic exclusion of se-
quencing artefacts and population variants, PDF provenance and
quality reports. Cpipe produces a clinically interpretable report avail-
able in Excel format. Results can be optionally imported into an
LOVD (Leiden Open Variant Database) instance for curation. Cpipe is
available at http://cpipeline.org.
Conclusion
Cpipe offers an open source solution that any clinical laboratory can
employ, either as their main analysis pipeline or as a benchmark for
comparison to improve their results.
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Objectives
This project aims the formulated algorithm will be implemented expli-
citly on lung cancer pathological images. Specifically, this project has
two goals. First, it aims to apply the concept of deep neural networks to
supervised learning in the classification of images, with the understand-
ing that modifying existing machine learning methods to target specific
image sets can optimize the precision and accuracy of the analysis. The
algorithm that will be formulated will be able to sort a given set of data
(in this case, images) into desired sets with given qualifications. Second,
it aims to apply the concept of deep neural networks, supplemented by
Bayesian networks to pattern analysis of lung cancer data sets. Perform-
ing Bayesian network procedures on given lung cancer data can help
us determine parameter values that will characterize those data. In turn,
those parameters can be used to infer whether or not new data can be
classified with the given training data or otherwise.
Methods
First, we take tiles of size 512x512 from images published on the
cancer genome atlas database (http://cancergenome.nih.gov). Several
samples from those 512x512 will be segmented further into 32x32
subregions, which will be used as an example training dataset. We
then incorporate the Sobel operator feature detection method, along
with the standard RGB image histogram to serve as the main fea-
tures for classification. These features will be extracted through the
notion of deep neural networks. The algorithm will then return a
classification of the subregions into either normal or abnormal, by
virtue of a Bayesian classification scheme.
Results
3,233 tiles of size 512x512 were gathered from two whole-slide lung
cancer images. Samples from these tiles were segmented further into
32x32 subregions, which served as training data for the algorithm.
The main output will be an algorithm embedded in a web applica-
tion wherein the user can just input newly acquired images, and the
program can provide classify which 32x32 subregions depict cancer
cells. A demonstration of the application can be shown during the
presentation.
Conclusion
An executable program, whose input is a lung cancer image, will be
segmented into 32x32 subregions, each of whose features will be ex-
tracted using deep neural networks and will undergo a Bayes’ classifi-
cation scheme, and determine whether the subregion is normal or
abnormal, either because of a broken cell, a stained cell, or an actual
cancer cell.
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Objectives
The increasing amount of heterogeneous genomic datasets gener-
ated today necessitates a robust platform for efficient data manage-
ment and analysis. To address this need, we developed a software
for the Management, Analysis, and Visualization of sequence data
(MAV-seq), capable of addressing the issues related to the exponen-
tial growth of genomic applications and their datasets of enormous
size and diversity. Our software also integrates various genomic pre-
processing pipelines with user-friendly graphical interface to enable
biologist with no programming experience conduct complex data
analyses.
Methods
MAV-seq (Figure) is a desktop application developed to integrate bio-
informatics methods, software engineering principles, human com-
puter interaction guidelines and big data analytics. The graphical
user interface (GUI) and back end development of MAV-seq is per-
formed in Java and Python, and schemas for backend data storage
are implemented in MySQL and MariaDB relational database man-
agement systems. MAV-seq allows direct data manipulation using
GUI as well as data import and export in “csv” file formats.
Results: We developed MAV-seq as an interactive, user friendly, cross
platform, encrypted and multi-roles based system for the manage-
ment of sample repertoires and automation of the data pre-
processing of epigenomic and transcriptomic data. It supports users
in performing downstream data analysis by integrating several ana-
lysis pipelines for diverse data sets including ATAC-seq, mRNA-seq,
tRNA-seq, Chip-seq, WES, WGS. MAV-seq can be customized for in-
creasingly large scaled and complex datasets of different types.
Moreover, it can directly interact with multiple data clusters to locate,
input and process genomics data by automatically generating and
running multiple-sequential and parallel pipelines.
Conclusion
MAV-seq is a comprehensive data management and analyses plat-
form that is newly designed, developed, tested, validated and de-
ployed at The Jackson Laboratory for Genomic Medicine. With this
platform, we aim to advance genome-wide big data management,
standardization and automation, which will expedite the pace and
improve the levels of efficiency in loading, handling, tracking, secur-
ing, sharing, processing, analyzing and visualizing data.
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Objectives
Tibetans have shown their physiological phenotypes adaptive to
hypoxia environment, including relative low hemoglobin concen-
tration and higher oxygen saturation. Among tens of candidate
genes revealed by various studies that relate to living in high
altitude, EPAS1 and EGLN1 showed strongest selection signals as
well as solid correlation to lower hemoglobin concentration in Ti-
betans. However, several tens of Tibetan specific SNPs in EPAS1
were all found in introns and the mechanism of this important
gene contributing to genetic adaptation in Qinghai-Tibet Plateau
is still elusive. This study aims at the function of Tibetan specific
SNPs in EPAS1.
Methods
1) 82 candidate genes were designed for capture and sequen-
cing in 45 Tibetans samples to discover more SNPs for further
association and functional studies. 2) Statistical tests including
Chi-square tests, haplotype association, and integrative Haplo-
type Score, and Refseq and NONCODE were used for annotation.
3) Cell culture of HepG2 and HEK293 under normoxia and hyp-
oxia (1%) for all functional assays. 4) Enhancer validation in a
dual-luciferase reporter system. 5) Circular chromosome conform-
ation capture (4C) in HepG2 followed by sequencing in Hi-Seq
2000.
Results
By re-sequencing 82 genes selected from previous studies and
our recent discoveries, totally 9947 SNPs were revealed in 45 Ti-
betan individuals (15 from Bomi; 20 from Anduo; 10 from Din-
gri). Six genes were consistently identified by three statistical
tests. In addition to EPAS1 and EGLN1, studies on quantitative
traits identified DISC1 and EDAR in association with diameter of
Main Pulmonary Artery and SaO2, respectively. By integrating
enhancer annotation data from FANTOM5 and ENCODE, 12
EPAS1 intronic regions were resulted. Further validation for the
enhancer function demonstrated that three of them are true en-
hancers. Moreover, enhancer 1 showed an allele specific activity
in both HepG2 and HEK293 cell lines. Especially, two Tibetan-
Han divergent SNPs showed the addictive effect in enhancer ac-
tivity. Further 4C-sequncing results of Enhancer 1 demonstrated
the similar chromosomal conformation structures in most en-
hanced regions under hypoxia and normoxia treatments but a
few interactions were shown to be hypoxia sensitive. Annotation
with Refseq and NONCODE database revealed that targets po-
tentially regulated by Enhancer 1 were mostly non-coding RNAs.
Conclusion
An allele-specific enhancer in EPAS1 intronic region may contribute
to high altitude adaptation in Tibetans.
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Objectives
Genome structural variations (SV) have been well established to
be associated with diseases and traits; however, SV analysis of
human genomes has been severely limited to date by technical
shortcomings. Traditionally, SVs have been detected by micro-
array (limited to imbalanced copy number variation (CNV) with a
short dynamic range, low resolution, and relative readouts), next-
generation sequencing (NGS) (primarily CNV, some balanced
events but too short to span most repeats) and karyotyping and
fluorescence in situ hybridization (FISH) (both are very low
resolution).
Methods
Using a single-molecule genome analysis system, BioNano Genomics
Irys® System, utilizing next-generation mapping (NGM) technology, it
is now possible to comprehensively analyze whole genomes for
SVs > 2 kilobase pairs (kbp), including balanced events in a cost-
effective and high-throughput manner. This technology allows for
the comparison of family pedigrees and populations, which is
needed to potentially uncover genomic structural causes of Men-
delian and complex diseases.
Results
We demonstrate the robustness of NGM for genome-wide discov-
ery of structural variation in the CEPH trio set from the 1000 Ge-
nomes Project where the individuals were sequenced and
analyzed in-depth. We generated de novo assemblies that cov-
ered at least 96% of the hg38 reference assembly. Compared to
tens of large SV events detected by NGS, we uncovered hun-
dreds of insertions, deletions, and inversions greater than 5 kbp,
a large portion of which was novel, and some are located in the
regions likely leading to disruption of gene function or regula-
tion. Based on the pedigree structure, we estimated that the
Mendelian concordance rate was 96%. We have also begun ana-
lysis of a trio of Ashkenazi Jewish descent from the NIST GIAB
project, where we have found hundreds of inversions, insertions,
and deletions, including large deletions in the UGT2B17 gene (in-
volved in graft versus host disease, osteopathic health, and tes-
tosterone and estradiol levels) in the mother and son.
Conclusion
We show that NGM is a robust and effective method for structural
variation detection in the human genome. Systematic whole genome
structural variation within disease population cohorts is needed, in
additional to the conventional SNP analysis, to study the effects of a
full spectrum of genomic variations in human disease and complex
traits.
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Objectives
The investigations of the indigenous populations from Malaysia and
their migration history have been scarce. In this study, we performed
the whole genome sequence for Malaysian indigenous (MI) genomes
from Peninsular Malaysia (PM) and Northern Borneo (NB). The gen-
omic structures of these samples were assessed, followed by identifi-
cation of the archaic genomes introgression between these samples
with Denisovan and Neandertal.
Methods
Seventeen genomes from indigenous populations from PM and NB
were sequenced using Illumina Hi-Seq, thus unveiled the full spectrum
of genetic architecture of the MI. Population genetic structure of these
samples were assessed with PCA and ADMIXTURE. Inference of coales-
cent time and effective population size were performed using PSMC,
and gene flow was estimated using TreeMix. Archaic genomes intro-
gression was estimated using the D-stat and f-test. S* analysis was ap-
plied to identify the introgressed genome segments.
Results
The divergence between Negrito and Austronesian occurred ~20K
years ago, and were gradually replaced by the Austronesian expan-
sion. Events of multiple gene flow into PM and NB was observed, in
line with previous investigations. However no evidence of signifi-
cantly higher gene flow from archaic genomes to MIs was observed,
and that the archaic DNA segments found in MIs were different from
those carried by the East Asia and Europeans.
Conclusion
Our analyses further strengthens the findings of the population struc-
ture of the indigenous people revealed by various earlier studies
using SNP array, yet suggests that the history of these populations
are far more complex than expected. The archaic genome introgres-
sion provided evidence of no significantly higher archaic genome
component in our samples. This preliminary study complements the
gaps of various speculations about archaic genomes introgression in
the regions of SEA and Oceanic.
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Objectives
Germline mutations in BRCA1 and BRCA2 confer high lifetime risk of
breast and ovarian cancer but importantly these risks are not irreversible.
Identification of asymptomatic carriers could significantly reduce the inci-
dence of these diseases. As a first step toward population based BRCA
gene screening, we are sequencing the entire coding region of 20 known
and proposed HBOC genes in 4,000 cancer-free Australian women.
Methods
Cancer-free women were selected from the LifePool study (www.life
pool.org) which is a cohort of women attending the Australian popu-
lation, based mammographic screening program. All exons of the tar-
get genes were enriched using the Haloplex system (Agilent) and
sequenced on a HiSeq2500 instrument (Illumina). The data were fil-
tered for known pathogenic or novel loss of function mutations.
Results
To date, data from 1,997 women has identified 17 with actionable mu-
tations in BRCA1 (4 mutations), BRCA2 (9 mutations) or PALB2 (4 muta-
tions). All 17 women subsequently accepted an invitation to attend a
Familial Cancer Centre and then proceeded to formal clinical genetic
testing. In addition 4 women had pathogenic mutations in BRIP1.
Conclusion
Our unique pilot data directly demonstrates a population carrier fre-
quency of ~1% for pathogenic mutations in these recognized high
risk breast and/or ovarian cancer genes and that such testing is well
accepted by the screened population.
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Objectives
In order to conduct comprehensive analysis of whole genome sequen-
cing (WGS) or whole genome bisulfite sequencing (WGBS), unbiased,
even coverage of the genome is required. To maximize time and cost
efficiency, it is imperative to attain coverage from the lowest possible
sequence read depth. Highly efficient conversion of DNA fragments
into library molecules is especially imperative when DNA input quantity
or quality is limited. To address these concerns, we have developed
two novel library preparations which enable highly efficient DNA library
preparation from low input while maintaining even genomic coverage.
Methods
The WGS method uniquely repairs damage on both the 3′ and 5′ ter-
mini to enhance ligation efficiency to DNA fragments. Combined with
sequential ligation steps, this single tube method supports PCR-free se-
quencing from inputs as low as 10 ng circulating, cell-free DNA (cfDNA)
or 50 ng physically sheared DNA. For WGBS, our library preparation is
performed on denatured, bisulfite-converted fragments. This improves
library recovery significantly compared to traditional library prep me-
thods that ligate methylated adapters to double-stranded DNA prior to
bisulfite conversion. Our adapter attachment to single-stranded DNA
supports inputs from 100 pg to 10 ng Input quantities down to 10 pg
can be used with PCR amplification.
Results
Using the WGS method, library conversion efficiency was ~50% for
physically sheared DNA and up to 90% for cfDNA. Human WGS using
this method demonstrates high complexity with exceptional coverage
of GC-rich promoter regions. At inputs as low as 1 ng human DNA, at
16X coverage, the genome was fully represented with consistent, uni-
form coverage. Libraries made with the WGBS method required less
PCR amplification than other available kits and this improvement was
further seen in the sequencing data, particularly at 1 ng input. Human
WGBS demonstrated comprehensive coverage of CpG islands when 10
ng input was used at low depth of sequencing. This library preparation
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method enables single base resolution of methylation status through-
out the genome, even from limiting DNA input quantities.
Conclusion
We have demonstrated the utility of increasing the efficiency of li-
brary preparation as a means of improving sequencing results ob-
tained through both WGS and WGBS. This innovative technology
enables sequencing of sample types that have been previously un-
usable due to input or quality limitations.
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Objectives
With drastic drop in the cost of whole genome sequencing (WGS) on
Illumina’s HiSeqX systems, it’s now economically feasible to plan large
scale sequencing projects in research as well as clinical settings.
However, successful execution of such projects will require design of
robust sample preparation (library) workflows that can work with a
spectrum of DNA quality and quantities. This is especially true for the
highly desirable PCR-Free libraries that are known to provide im-
proved gene and genome representation compared to PCR amplified
libraries. Here we discuss the use of multiple PCR-Free protocols for
use on HiSeqX.
Methods
Previously we automated Illumina TruSeq PCR-Free protocol, which is
recommended to use with 1 ug of good quality DNA to prepared
size selected libraries. However, to broaden the scope of samples
that can be used for preparing PCR-Free libraries, we evaluated two
additional library construction methods 1. Swift Biosciences 2S library
kit and 2. Kapa Biosystems, hyper prep kit. PCR-Free libraries were
prepared using 200 ng - 1 ug DNA of HGSC internal human control
sample (HS1011) with these kits and sequenced on HiSeqX to gener-
ate 34-38X genome coverage data.
Results
Exome representation as measured by complete coverage of Online
Mendelian Inheritance in Man (OMIM) genes at 20X read depth was
lowest for the TruSeq PCR-Free libraries (2687 genes) when com-
pared to the 2S libraries (2750 – 3020 genes) and the Kapa hyper li-
braries (2800 genes). GC representation was better in PCR-free
libraries when compared to the TruSeq Nano libraries. Kapa Hyper
protocol was optimized on Beckman Coulter’s Biomek FXP liquid
handler using 500 ng DNA and can prepare 96 libraries in ~ 6 hours.
This protocol also works well with DNA of different integrities. En-
hancements have also been made for precise quantification of PCR-
Free libraries by qPCR and to eliminate unused adapter molecules in
libraries that can impact sequencing.
Conclusion
Availability of such robust and automated protocols has positioned
us to efficiently work with large sample sets to fully exploit the use
of HiSeqX platforms for population level genomic studies and to
drive its use in clinical setting.
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Objectives
Advancement of next generation sequencing in clinical settings has
required methods for rapid, robust delivery of high-quality sequen-
cing data. Effective and timely diagnoses or prediction of risk of gen-
etic diseases are important for medical intervention.
Methods
We have developed a ‘lightning capture’ process to deliver variant
calls in 5–7 days after sample intake. This process includes: quick en-
richment library preparation (5–6 hours), capture enrichment (about
8 hours), rapid sequencing (Illumina HiSeq2500) and data analysis via
the HGSC-developed Mercury pipeline. The lightning capture proto-
col has been deployed in BMGL clinic lab for whole exome sequen-
cing (WES) and recent carrier screening with a novel 500kb carrier
mutation gene capture panel. Our WES design contains 3643
clinically relevant genes primarily from GeneTests and OMIM, and
the carrier panel includes 168 complete genes that contain at least
850 known common genetic variants of clinical relevance. We also
employ the genotyping with SNPTrace panel by Fluidigm in order to
ensure reliable sample identification, and to test for sample cross-
contamination.
Results
This method has been validated with ~500 WES and more than 5000
carrier samples. WES samples are processed in single capture or 3-plex
co-capture, while carrier samples are in a cost-effective 47plex co-
capture format for hybridization followed by sequencing of 94 samples
(2 capture pools) per HiSeq 2500 lane. High enrichment efficiency
was observed (72-80% reads on target and buffer) and superior
coverage metrics across the design with 11 Gb sequencing yield for
WES and ~400 Mb for Carrier samples. A detailed analysis of the
carrier design performance using 140 de-identified samples found
that known carrier mutations were correctly identified with high
confidence (98.5%), including large/complex indel mutations.
Conclusion
Sample turnaround time for tests is often considered one of the
most significant measures of performance for a clinical lab. The
lightning capture process we developed enables data delivery in 5–7
days without sacrifice of data quality. This novel method may impact
applications in prenatal, neonatal intensive care and other critical set-
tings for clinical and research samples.
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Objectives
Generate a high quality reference genome from a single individual to
avoid limitations of the haploid mosaic human reference and explore
the contribution of different data types to understanding the com-
prehensive clinical genome.
Methods
Illumina data from a variety of libraries (180 bp, 300 bp and 500 bp
paired end data; 3kb, 6.5 kb and 8 kb mate-pair data), as well as Illu-
mina Hi-C data, 20x PacBio RS long read data and BioNano optical
mapping data were produced and assembled de novo. Structural var-
iants that are difficult to characterize with exome sequencing or
short sequence reads from small fragments were identified using
two methods. We identified putative novel insertions in reads that
did not map to the GRCh38 reference with calls supported by 6.5 kb
mate-pair data, and confirmed in the de novo WGS assembly contigs
and 3 kb mate-pair data. We identified tandem duplications with
combined signatures of inverted 300 bp to 500 bp read pairs identi-
fying the boundaries and larger read pairs confirming the size of the
duplicated region.
Results
We report here the assembly of data from a single individual
(HS1011). The data are available at NCBI under BioProject 203659.
The released assembly is highly contiguous with a 394 kb Contig
N50 and 148 Mb Scaffold N50 with full chromosome scaffolds. Data
from the parents of HS1011 and long-read data allow us to phase
variants within this genome. Putative novel insertions (78) and tan-
dem duplications (70) were identified.
Conclusion
The assembly and underlying data reported here allow us to op-
timize methods to combine these data types and explore the utility
of the different data types to identify structural variation and define
which heterozygous variants are located on the same haplotype for
haplotype-aware downstream analyses.
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Objectives
Discoveries of chromosomal alterations ranging from single nuc-
leotide variants (SNVs) to large structural variants (SVs), via next-
generation sequencing (NGS) techniques, have drastically impacted
the delineation of genomic architecture and disease mechanisms.
However, in contrast to being able to identify SNVs efficiently and
accurately, current short-read NGS platforms have been inefficient
for discovery of complex chromosomal rearrangements. To detect
chromosomal pathogenic SVs, we have developed a novel method,
Pacific Biosystems large insert targeted capture-sequencing (PB-LITS).
We further tested PB-LITS protocol for detection of clinical relevant
complex gene structural mutations with a set of 6 breast cancer
samples.
Methods
Genomic DNA was fragmented to 6kb and ligated with Illumina
adaptors, followed by size-selection at 4.5kb-9kb range. Long range
PCR was performed on size-selected inserts. Pre-Capture PCR prod-
ucts were hybridized with a set of NimbleGen SeqCap probes target-
ing 94 genes that represent a spectrum of diseases with low, and
thus unsatisfactory, sequencing access by current short-read NGS
methods. Captured products were processed by standard PacBio
large insert library preparation procedure. The final product, a 6kb in-
sert capture library with single molecule, real-time (SMRT) bell adap-
tors, was sequenced on PacBio RSII platform.
Results
Initial PB-LITS protocol has shown its value of discerning complex
structural rearrangements with 1.5ug input DNA1. Further develop-
ment of PB-LITS enabled successful construction of 6kb-insert cap-
ture library with minimal 150ng input, by optimizing adaptor ligation
and long range PCR reaction. Sequencing with 2~3 SMRT cells of
HapMap DNA libraries constructed by current protocol yielded 20x
coverage of 93% of 14mb target size with an average insert size of
3.7kb-7.1kb. Sequencing and further analysis of the libraries con-
structed from 6 cases with strong family histories of breast cancer
who previously tested negative for mutations in BRCA1 and BRCA2
are undergoing.
Conclusion
Optimized PB-LITS protocol provided a reliable research tool for
studying complex chromosomal SVs. Development of library con-
struction procedure of PB-LITS has laid solid foundation to employ
the method in clinical settings where identification of pathogenic
complex SVs with limited sample amount is challenging.
References
1. Wang M, et al. PacBio-LITS: a large-insert targeted sequencing method
for characterization of human disease-associated chromosomal
structural variations. BMC Genomics. 2015; 16:214.
Disclosure of interest
None declared.
O58
Rhesus macaques exhibit more non-synonymous variation but
greater impact of purifying selection than humans
R. A. Harris1,2, M. Raveenedran1,2, C. Xue1,, M. Dahdouli1,2, L. Cox3, G. Fan4,
B. Ferguson5, J. Hovarth6, Z. Johnson7, S. Kanthaswamy8, M. Kubisch9,
M. Platt10, D. Smith11, E. Vallender12, R. Wiseman13, X. Liu14, J. Below15,
D. Muzny1,2, R. Gibbs1,2, F. Yu1,2, J. Rogers1,2
1Molecular and Human Genetics, Baylor College of Medicine, Houston,
TX, USA; 2Human Genome Sequencing Center, Baylor College of
Medicine, Houston, TX, USA; 3Genetics, Southwest National Primate
Research Center, San Antonio, TX, USA; 4Human Genetics, Univeristy of
California Los Angeles, Los Angeles, CA, USA; 5Division of Neuroscience,
Oregon National Primate Research Center, Beaverton, OR, USA;
6Genomics & Microbiology Research Laboratory, NC Museum of Natural
Sciences, Raleigh, NC, USA; 7Yerkes Nonhuman Primate Genomics Core,
Yerkes National Primate Research Center, Atlanta, GA, USA;
8Environmental Toxicology, California National Primate Research Center,
Davis, CA, USA; 9Physiology, Tulane National Primate Research Center,
New Orleans, LO, USA; 10Neuroscience, University of Pennsylvania,
Philadelphia, PA, USA; 11Anthropology, University of California Davis,
Davis, CA, USA; 12Psychiatry and Human Behavior, University of
Mississippi Medical Center, Jackson, MS, USA; 13Genetics, Wisconsin
National Primate Research Center, Madison, WI, USA; 14Epidemiology,
Human Genetics & Environmental Sciences; 15Epidemiology and Disease
Control Human Genetics Center, University of Texas Health Science
Center, Houston, TX, USA
Correspondence: R. A. Harris – Molecular and Human Genetics, Baylor
College of Medicine, Houston, TX, USA
Human Genomics 2016, 10(Suppl 1):O58
Objectives
We generated whole genome sequence data for 133 rhesus ma-
caques (Macaca mulatta), the primary nonhuman primate in biomed-
ical research.
Methods
Using the intersection of GATK and SNPTools SNV calls, we identified 43
million high-quality SNVs, including >126,000 missense and >148,000
synonymous coding variants.
Results
Comparisons with equivalent whole genome data from the Human
1000 Genomes project shows that macaques have 2.5-fold higher
levels of overall variation and 20% higher levels of nonsynonymous
variation per individual. Comparing the ratio of nonsynonymous to
synonymous variants between species shows a lower ratio of NS:Syn
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in macaques, indicating more effective purifying selection, which can
be explained by higher effective population size. Looking more spe-
cifically at 740 genes from the SFARI autism genetic association data-
base, the ratio of NS:Syn variants among the macaques is lower in
the SFARI gene set than in the complete macaque gene set.
Conclusion
These data suggest that large effective size in macaques leads to
higher levels of both total and nonsynonymous variation than
humans, and that purifying selection in macaques is more efficient in
restricting mildly deleterious mutations.
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Objectives
It has been challenging to interpret noncoding variants in complex
traits and human diseases. RiboSNitches, single-nucleotide variants
(SNVs) that alter the structures of RNAs, have recently found in many
human diseases. RNA structure change mediated by riboSNiches has
emerged as a plausible mechanism of pathogenic consequences of
mutations. Thus, it is desirable to automatically predict riboSNitches
from millions of SNVs of the human genome. However, current com-
putational methods based on in silico RNA-folding algorithms suffer
from limited accuracy. We seek to develop a new method for im-
proved riboSNitch detection.
Methods
We introduce a new measurement to quantify the structural differ-
ence between the wild-type and mutant RNAs in which the two se-
quences are differed by an SNV. The new measurement is based on
assessing the consistency of RNA structure change of individual
bases. Using this new measurement, our method automatically se-
lects a region that maximizes the effect of RNA structure disruption
induced by an SNV.
Results
We applied our method to analyze a genome-scale dataset of riboS-
Nitches and non-riboSNitches determined from the parallel analysis
of RNA structure experiments on a family trio of human lymphoblas-
toid cell lines. The dataset contains rigorously validated subsets of 11
“probed”, 63 “validated”, and 223 “symmetric” riboSNitches. We
found that our method consistently outperforms other existing
methods on these rigorously validated subsets of riboSNitches.
Conclusion
Our new method improves the accuracy of computational prediction of
riboSNitches. It facilitates the prioritization of noncoding variants for
interpreting personal genomes. It also holds the promise to identify
disease-causing variants potentially through RNA structure disruption.
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Objectives: Variation in mitochondrial DNA (mtDNA) copy number
(CN) has been shown to be related to the risk of several cancers in
prospective studies. The inter-individual variability of mtDNA CN is
thought to be partially heritable; however, no genome-wide associ-
ation study (GWAS) of the nuclear genome has yet been performed.
Methods: We conducted a meta-analysis of GWAS of peripheral
blood mtDNA CN using data from participants of European ancestry
from nested case–control studies of prostate cancer and non-Hodgkin
lymphoma in the Prostate, Lung, Colorectal, and Ovarian (PLCO)
Screening Trial (n=1664). MtDNA CN was natural log-transformed and
linear regression was used to evaluate the association, assuming an
additive genetic model and adjusting for age at mtDNA blood draw,
ancestry, and sex. The three GWAS were combined in a fixed-effects
meta-analysis.
Results: A quantile-quantile plot of the association results revealed
some enrichment for SNPs with small p-values, but no evidence of
genomic inflation (λ=1.007). Six loci, defined as +/− 1 Megabase,
reached genome-wide significance (p < 5X10−8), but all appeared to
be singletons, indicating that they are likely to be false positives. Ten
Single Nucleotide Polymorphisms (SNPs) in an intronic region of the
long-range sonic Hedgehog signaling gene, DISP1, were found sug-
gestively associated (p < 5X10−5)with mtDNA CN, with consistency in
the direction of associations among all three GWAS.
Conclusion: Preliminary findings from this meta-analysis suggest that
there may be common genetic variants of the nuclear genome associ-
ated with mtDNA CN. We are currently augmenting our meta-analysis
by including additional GWAS of nested case–control studies in PLCO
and the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study. We
expect that the added statistical power will yield novel loci for mtDNA
CN and provide new insight into the regulation of mtDNA CN.
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Objectives: Single nucleotide polymorphisms (SNPs) drawn much at-
tention as prospective biomolecular markers for human health man-
agement and disease therapies. Moreover SNPs have been surmised
to constitute unique genetic makeup characteristic to each human
individual, which can be utilized to cater therapeutic approaches to
personalized medical care. Down syndrome (DS) or trisomy 21 is the
most frequently occurring birth-related defects affecting live-born
children. Molecular mechanisms that regulate and/or result in the
formation of trisomy 21 in DS mothers, remain hitherto unknown.
We posit a genetic basis for disposition of DS occurrence. We there-
fore performed bioinformatics studies of published nonsynonymous
SNPs in conjunction with structural information of the proteins
encoded by DS risk genes in the attempt to identify novel governing
principles of DS risk.
Methods: We surveyed all SNPs in the published literature focusing
on missense mutations, and superimpose on bioinformatic recon-
struction of secondary structural motifs of proteins encoded by DS
genes
Results: In our survey, we observed that even the most penetrant
SNP implicated in DS is not completely associated with the disease.
On the other hand, a combination of co-occurrence of SNPs is im-
portant, suggesting a synthetic cooperation between missense muta-
tions to underlie occurrence of DS phenotype. Superimposing
documented SNPs from several public databases showed a preferen-
tial localization of these SNPs with specific structural motifs within
the proteins. Interesting, we noticed several closely situated SNPs
that have not been reported to be associated with DS risk within reg-
ulators of the one carbon folate metabolism that included reduced
folate carrier 1 (RFC1) and methionine synthase. These may represent
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novel SNPs that can be assessed experimentally in a targeted man-
ner in future population studies.
Conclusion: Taken together, our analyses showed that SNPs that re-
sult in change of protein sequences act synergistically to impact DS
phenotype and suggest that SNP combinations to be a more reliable
criteria than single SNPs for ascertaining DS risk, at least in the case
of missense SNPs. Our study also identified probable secondary
structural motifs implicated in DS risk-associating factors. These re-
sults will form the basis for future experiments that may hold potential
for translation into personalized diagnosis or therapeutic management
of DS.
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Objectives: To determine the minimum number of genes (dimension
of the problem) and their network organization in the distinction
between Crohn’s Disease (CD), Ulcerative Colitis (UC) and normal pa-
tients (N).
Methods: We relied on the results published by Burczynski et al.
where transcriptional profiles in peripheral blood mononuclear cells
(PBMC) from 42 healthy individuals, 59 CD patients, and 26 UC pa-
tients were assessed. We applied a newly proposed gene selection
method, based on statistical and machine-learning principles, which
finally delivered a set of models which best predicted the disease
class. These models were inserted in a network where the biomarkers
were placed in specific positions according to their relevance in dis-
criminating between the diseases.
Results: We found that a set of models, each containing only two
RNA’s from the PBMC, were sufficient to discriminate CD from UC pa-
tients and normal individuals. These RNA’s were organized in net-
works where the gene in first position could well classify when
placed in a model with any of those in the corresponding second
position. A summary of these networks is as follows.
Conclusion: Our statistical method is a new powerful tool that gives
(1) the dimension of the statistical model, (2) the network organization
of the selected genomic biomarkers, (3) a set of interchangeable
models giving the same information.
Moreover, all the RNA’s in position 1 of the selected networks are
known to have a clinical significance in Inflammatory Bowel Diseases.
Amyloidosis is a well-known complication of CD and UC (Amyloid
beta A4 precursor protein). Chemotaxis and neutrophil activation are
fundamental pathways in the pathogenesis of IBD (Chemokine C-X-C
motif ligand 5). RAB31 enhances FcγR-mediated phagocytosis
through PI3K/Akt signaling in macrophages and plays a role in the
maturation of phagosomes. Some clinical evidence links the men-
strual cycle to the IBD activity (Progesterone receptor membrane
component 1).
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Objectives: Single nucleotide polymorphisms (SNPs) have been re-
ported in different autistic populations. Here we present the first as-
sociation study investigating SNPs of some genes; serotonin receptor
(HTR2A IVS2A>G rs7997012; HTR2C 68G>C rs6318), serotonin trans-
porter (SLC6A4 rs3813034), ankyrin repeat and kinase domain contain-
ing 1(ANKK1 rs1800497), methylenetetrahydrofolate reductase (MTHFR
rs1891394), and BDNF rs6265 in Saudi autistic children. Epidemio-
logic, clinical and psychometric aspects were used to examine the
possible risk factors of autism.
Methods: We used TaqMan SNP genotyping to examine 68 Saudi
children (48 Males and 20 females) diagnosed with autism according
to DSM-IV criteria & ICD-10 criteria, including deficits in reciprocal so-
cial interaction, impaired verbal, and non-verbal communication as
well as restricted, repetitive, and stereotyped patterns of behaviors.
Healthy controls (n= 78) with no history of mental illnesses, be-
havioral disorders or substance abuse were used. The severity of be-
havioral symptoms in cases was assessed at admission using the
Childhood Autism Rating Scale (CARS). Hardy-Weinberg equilibria of
the genetic variants were assessed using online software (http://
www.oege.org/software/hwe-mr-calc.shtml). Chi-square tests were
used to compare sociodemographic and clinical characteristics. Odds
ratios and confidence intervals were calculated.
Results: Overall, our data provide strong evidence of associations be-
tween these two SNPs and risk of autism in this population. Com-
pared to healthy subjects, children with autism showed significant
overexpression of the mutant alleles in the SNPs rs7997012, rs6318,
rs3813034, rs1800497, and rs1891394, but not in the rs6265 SNP.
Data on linkages or associations between these genetic loci and the
disease vary among different ethnicities.
Conclusion: Our findings presented associations between autism and
some genetic variants under investigation, and showed that the po-
tential influence of just one copy of the mutant alleles in the Saudi
patients. Replicating our findings in other ethnic population may
support our data before making any firm generalizations. Ongoing
analyses of genetic variants associated with autism are being ex-
tended using next-generation sequencing and some fruitful data are
going to be published.
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Objectives: The majority of variants associated with common disease
reside in non-coding sequence. Efforts to understand complex dis-
ease risk thus focus heavily on regulatory variation. How to seek bio-
logically relevant sequences in which variation may reside and how
to make in vivo predictions of the impact and function of regulatory
variation remains a major challenge. We recently demonstrated how
GWAS results can be informed by enhancer analyses in homogenous,
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phenotype-appropriate cell populations. Further, such enhanced
datasets make feasible the prediction of functional variants. Pres-
ently, we are leveraging our past experiences to generate enhancer
catalogues using homogenous populations of dopaminergic (DA) neu-
rons better to understand the role of regulatory variation in Parkinson
Disease (PD) and related disorders.
Methods: We assayed open chromatin regions using ATAC-seq, pro-
ducing multiple enhancer catalogues. Each catalogue is generated
from 50,000 FAC-sorted DA neurons from either the forebrain (n=3 li-
braries) or midbrain (n=3 libraries) of E15.5 transgenic mice. Each
ATAC-seq library is of high quality, yields over 30 million reads se-
quenced, with over 28 million reads mapping, and following filtering
of reads, MACS2 calls ~50,000 peaks, indicating intervals of open
chromatin.
Results: Our preliminary analyses indicate that peaks from all li-
braries show evidence of functional sequence constraint (PhastCons
scores>0.3) and significant enrichment for processes and functions ap-
propriate to neuronal function/dysfunction by GO/GREAT. The high
quality of these open chromatin signatures also facilitate development
of a computational classifier (regulatory vocabulary) of DA neurons.
Consequently, we have begun to gain further insight into the transcrip-
tion factors active in DA neurons and the nature of variation that might
influence the function of identified DA enhancers.
Conclusion: We are currently validating the DA neuron enhancer
catalogues in vivo and are evaluating the shared and unique content
of the catalogues and their pertinence to disease. Additionally, we
have generated single cell and bulk RNA-seq from these isolated
populations to corroborate and inform our chromatin-based findings.
With this data in hand, we are able to assay the impact of PD and re-
lated movement disorders’ GWAS-implicated variation on DA neuron
function and disease pathogenesis.
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Objectives: To identify and characterize genetic modifiers capable of
altering the retinal dysplasia observed in Nr2e3rd7 mutants, a model
for human Enhanced S-Cone Syndrome (ESCS).
Methods: Nr2e3rd7 mice were chemically mutagenized, and mated to
generate a G3 population. The G3 mice were screened by indirect
ophthalmoscope to establish lines bearing genetic modifiers that al-
tered the pan retinal fundus spotting phenotype, characteristic of
homozygous Nr2e3rd7 mice. Quantitative trait locus analysis combined
with high-throughput sequencing of an exome capture libraries was
used to identify the molecular basis of modifiers of the retinal dysplasia
in Nr2e3rd7 mutants. Apart from fundus imaging, longitudinal histo-
logical studies were carried out to characterize the progression of al-
tered retinal phenotypes. Finally, immunoblotting and marker analyses
were performed to reveal the defects that underlie the rd7-retinopathy
and how the defects were affected by the modifier(s).
Results: Seven heritable modifier mouse lines with an altered retinal
phenotype have been established so far. Among them three poten-
tial genetic modifiers have been identified, which directly or indir-
ectly are associated with growth and development of neuroretinal
cells. For example, the Tvrm272 line bears a nonsense mutation
of the Rarb gene, which leads to a vitreal dysplastic phenotype
that is more severe in the presence of the Nr2e3rd7 mutation. While a
reduced retinal spotting phenotype and suppression of formation of
rosette-like structures associated with the rd7 retinopathy in the
Tvrm222 line is due to a missense mutation in the Frmd4b gene. The
modifying effect of the Frmd4bTvrm222 allele is achieved through its ef-
fect on cell-cell junctions, revealed by immunoblotting and marker
analysis.
Conclusion: As an animal model of ESCS, retinal dysplasia in Nr2e3rd7
mouse can be phenotypically altered by multiple genetic modifiers
via different pathways. The modifying effects on rd7-associated reti-
nopathies by these particular genetic modifiers, to our knowledge,
are the first to be described. They provide novel insights into the
pathogenesis of retinal dysplasia as well as degeneration in Nr2e3rd7-
associated disease, and may become potential interfering targets for
clinical applications against ESCS and related retinopathies.
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Objectives: Targeted customized sequencing of genes implicated in
the Autosomal recessive polycystic kidney disease (ARPKD) pheno-
type to identify candidate variants using next-generation sequencing
by Ion torrent PGM.
Methods: Eighteen unrelated ARPKD probands and healthy human
adult control samples were recruited for genetic screening of ARPKD
at a referral hospital from northern region of Saudi Arabia. Probands
had survived the neonatal period and had age range in between 2
months to 13 years.
Ion-Torrent PGM sequencing: We have customized primers and a tar-
get enrichment kit for targeting of the ARPKD candidate gene
(PKHD1), and also included the PKD1 and PKD2 genes that may
mimic the phenotype of the ARPKD. The NGS protocol involves three
steps (1) Library preparation (2) Template preparation, finally sequen-
cing was performed on PGM using Ion PGM 200 sequencing kit.
Mapping assembly and variants discovery from NGS data: For each re-
sulted deleterious variants identified by NGS were also confirmed by
Capillary sequencing.
Results: We identified five potential pathogenic missense variants in
PKHD1 gene in 12 ARPKD Saudi patients. One missense variant was
novel and other four had been reported in other ethnic groups but
not in Saudis. The rest of the patient’s samples have few variants in
PKD1 and PKD2 genes that were not in damage but two causative
variants observed. One missense homozygous variant c.4870C>T,
p.(Arg1624Trp) was common in eight patients in PKHD1 gene de-
rived from a male proband. Our results showed that the deleterious
missense variant detected in PKHD1 gene was pathological signifi-
cant or damaged were identified by computational predictions Sort-
ing Intolerant From Tolerant (SIFT) and Polymorphism Phenotyping
(PolyPhen2). Taken together, this strategy significantly lowers the
cost and time for simultaneous targeted genes sequence analysis,
and facilitating routine genetic diagnostics of ARPKD.
Conclusion: Overall, the NGS TargetSeq exome sequencing may
prove to be advantageous in the early diagnosis in patients with
ARPKD disease.
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Objectives: Neuronal cells are not homogeneously distributed and
subtypes are intermingled with each other as well as with non-
neuronal cells such as glia and blood vessel cells. When attempting
to digitally profile the expression of a specific type of neuron, retriev-
ing the RNA only of that cell type therefore poses a considerable
challenge. Our aim was to isolate RNA specifically from Purkinje neu-
rons in different parts of the cell body: soma (in different subcellular
compartments, cytoplasm and rough endoplasmic reticulum) and
dendrites.
Methods: In previous work, we used a technology called translating
ribosome affinity purification (TRAP) to isolate the ribosome-
associated transcriptome — the translatome. We modified it to tar-
get any cell type that can be specifically infected by a modified
adeno-associated virus, and applied it to Purkinje cells (PCs) in the
rat cerebellum. We obtained quantitative expression data in single-
base-pair resolution by profiling the ribosome-associated, isolated
RNA using the nanoCAGE protocol.
Results: Subsequent data analysis revealed the landscape of
ribosome-associated RNA of PCs in different subcellular compart-
ments: cytoplasm and rough endoplasmic reticulum in the soma. We
published these results in [1]. Building on this work, we have now
successfully retrieved RNA from dendrites in the same model system
with replicated libraries, and thus obtained a deep sequencing using
a newly developed protocol employing unique molecular identifiers
(UMI) for a more precise measurement of expression.
Conclusion: In neurons, protein translation occurs not only in the
soma but also distally in dendrites near or within the dendritic
spines. This distal translation is thought to be regulated in response
to external stimuli including long-term depression and memory for-
mation. We have applied TRAP to Purkinje dendrites and sequenced
the isolated RNA with an improved nanoCAGE protocol including a
tagmentation step, to address the increased difficulty of sequencing
from dendrites, which contain even less RNA than Purkinje cell soma.
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Objectives: Genomes are products of natural processes. Hence all ge-
nomes contain functional and nonfunctional parts. Here, I present a
functional classification of genomic elements and estimate the func-
tional fraction within the human genome.
Methods: The classification into different categories of functionality
were based on the concept of selected-effect function. Intraspecific
and interspecific genomic comparisons and standard evolutionary
methodology were used to infer the functional fraction within the
human genome.
Results: According to their selected-effect function, the genome is di-
vided into functional and rubbish DNA. Functional DNA is further
subdivided into literal and indifferent DNA. In literal DNA, the order
of nucleotides is under selection; in indifferent DNA, only the pres-
ence or absence of the sequence is under selection. Rubbish DNA is
further subdivided into junk and garbage DNA. Junk DNA neither
contributes to nor detracts from the fitness and, hence, evolves
under selective neutrality. Garbage DNA, on the other hand, de-
creases the fitness of its carriers; it exists in the genome because nat-
ural selection is neither omnipotent nor instantaneous. Each of these
four functional categories can be transcribed and translated, tran-
scribed but not translated, or not transcribed. The affiliation to a par-
ticular functional category may change during evolution: Functional
DNA may become junk DNA, junk DNA may become garbage DNA,
and so on; however, in the absence of prophetic powers determining
the functionality or nonfunctionality of a genomic sequence must be
based on its present status rather than on its potential to change in
the future. Changes in functional affiliation are categorized into pseu-
dogenes, Lazarus DNA, zombie DNA, and Jekyll-to-Hyde DNA. Intra-
specific and interspecific genomic comparisons indicate that the
functional fraction in the human genome ranges from 8% to 15%.
Conclusion: A common misconception exists according to which
evolutionary processes can produce a genome that is wholly func-
tional. Actually, evolution can only produce such a genome if and
only if the effective population size is infinite, the deleterious effects
of increasing genome size by even one nucleotide are considerable,
and the generation time is short. Not even in the commonest of bac-
terial species are these conditions met. In species with small effective
population sizes and long generation time, such as humans, a gen-
ome that is ~100% functional is contrary to reason.
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Objectives: Here we present a new method for the identification of
recurrent genomic entities that play a causative role in the onset of
disease. Our approach is particularly amenable for the analyses high-
throughput sequencing data.
Existing approaches often follow a bottom-up approach where taxo-
nomic determination necessarily takes place before associations to
disease can be determined; naturally failing to establish the causality
of novel pathogens not present in reference databases.
Methods: To overcome this intrinsic limitation, we have developed a
species-agnostic top-bottom approach that clusters sequences and
identifies co-occurrence in multiple patients, associates recurrent se-
quences to disease and, finally, determines the taxonomic content
where existing knowledge permits.
Results: We analysed 686 sequencing libraries from 252 cancer speci-
mens and 56 controls. Recurrent sequences were statistically associated
to biological, methodological and technical features to identify novel
pathogens and contaminants stemming from laboratory reagents.
Conclusion: We provide examples of identified inhabitants of the
healthy tissue flora, known experimental contaminants and
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uncharacterised sequences that co-occur with high statistical sig-
nificance with disease. The latter represent a category that can
only be addressed by a species-independent approach. Thus, our
method helps to chart the unknown sequence-space where novel
pathogens can be identified.
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Objectives: An active module which is densely conserved across mul-
tiple gene networks exhibit strong and conserved interactions among
its active member genes across all the networks. Identification of such
modules across multiple species using gene networks in stem cell differ-
entiation has provided new insights into evolutionary conserved devel-
opmental pathways and conserved pioneer factors. Similarly in cancer,
such modules (if exists) will represent core common carcinogenesis-
driving pathways in multiple types of cancer. These common pathways
can have the same prognosis in cancers stemming from different tis-
sues. Even though, a comprehensive amount of gene expression data
for multiple types of cancer has been acquired, there is no study on
comparison of several cancer gene networks. In this study, we perform
local alignment of 8 cancer gene networks to identify active gene mod-
ules which are densely conserved across the cancer types. We further
study the prognostic and mutation patterns within these modules.
Methods: We developed a computational framework to identify active
modules of genes which are densely conserved across 8 different types
of cancer by extending a previous tool called neXus to allow it to work
on more than 2 cancer gene networks. We identified 174 modules of
genes satisfying these three strict criteria – 1) member genes were dif-
ferentially expressed between normal and cancer tissues (FDR < 0.05)
in at least 7 cancer types of cancer of interest, 2) average fold change
of 2 in the member genes across all 8 cancer types and 3) the cluster-
ing coefficient of at least 0.5 in all the 8 cancer gene networks.
Results: The identified modules represented some known pathways
associated with multiple cancers such as the RAS pathway, but sev-
eral new genes which may play important in triggering cancer in
multiple types of tissues were discovered. We found that these con-
served modules of genes have high prognostic power in all the 8
types of cancer of interest. We also found that these active and con-
served modules exhibit similar mutually exclusive mutation patterns
among the gene members and these patterns were also conserved
across the majority of the types of cancer.
Conclusion: These findings reveal a new set of previously unknown
pathways, which most likely run as a common thread during carcino-
genesis in many cancer types and hence are worth investigating fur-
ther for experimental validation.
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Objectives: Oral leukoplakia (OL) is the most common precancerous
lesion in the oral cavity. The percentage of individuals with dysplastic
OL in whom there is malignant transformation to oral squamous cell
carcinoma (OSCC) is high, up to 36%. Germline and somatic copy
number variations in mitochondrial DNA of OL patients have earlier
been noted. We sought to test the hypothesis that about 36% of pa-
tients with the pre-cancerous lesion (OL) will possess somatic muta-
tions in genes that are recurrently mutated in OSCC.
Methods: Whole exome sequencing of DNA isolated from the af-
fected oral tissue and from peripheral blood of twelve OL patients
with dysplasia, was used to profile the landscape of autosomal som-
atic recurrent mutations in OL and to investigate whether mutations
in the genes that drive OSCC are present in OL patients or whether
the mutational landscapes of OL and OSCC are largely disjoint.
Results: We have detected mutations in some genes that drive both
oral leukoplakia and oral cancer. TGFBR2 is recurrently mutated in OL
as well as in head and neck squamous cell carcinoma (HNSCC). Some
significantly mutated genes in OSCC or HNSCC, viz., FAT1, NOTCH1
and CDKN2A are also found to be mutated in OL patients. Further,
we have identified that MAPK signalling and oxidative phosphoryl-
ation (OXPHOS) pathways are significantly altered in OL patients.
Conclusion: We have found that the proportion of OL patients with
epithelial dysplasia among whom mutations were found in the set of
genes that is also recurrently mutated in OSCC/HNSCC, closely corre-
sponds to the fraction (~36%) of patients with dysplastic leukoplakia
who develop oral cancer. The leukoplakia patients recruited in this
study were free of malignancy in the oral cavity; our results are,
therefore, not influenced by field cancerization.
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Objectives: BRCA2-induced breast cancers share a predominant histo-
logic and molecular phenotype (ER+, luminal B) that distinguishes them
from most sporadic breast cancers and breast cancers arising in other
inherited disorders. This suggests that breast cancers arising in
BRCA2-mutation carriers have essential shared properties that drive
carcinogenesis and can be targeted for intervention. To investigate
this observation, we performed a cell biological screen in non-
transformed breast epithelial cells for phenotypes specific to BRCA2
loss-of-function.
Methods: Non-transformed breast epithelial cells were treated with
siRNAs targeting hereditary breast cancer genes. Growth curves were
obtained in complete growth media and growth factor-withdrawal
medias. Whole genome sequencing and transcriptomics were per-
formed. Functional cell biological assays including treatment with re-
combinant cytokines and inhibitors were performed.
Results: Despite the role of BRCA2 in homologous recombination-
mediated DNA repair, no recurrent de novo mutations were reco-
vered. Instead, we discovered a novel pathway whereby BRCA2 de-
pletion induces strong, persistent transcriptional activation of the
chemokines on chromosome 4q13 (CXCL1, CXCL3, CXCL5, CXCL8).
Surprisingly, these chemokines were sufficient to stimulate EGF-
independent growth of non-transformed breast cells. Furthermore,
inhibitors of the receptors of the chemokines impaired cell prolifera-
tion after BRCA2 depletion.
Conclusion: Altogether, these findings indicate that transcriptional
activation of the 4q13 chemokine locus induces an early cell-
autonomous autocrine signaling pathway in BRCA2-mediated car-
cinogenesis that could be exploited to prevent cancer onset.
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Objectives: RNA sequencing (RNA-seq) is a powerful tool used for the
interrogation of transcripts that enables the analysis of gene expression
and the identification of nucleotide or structural variations. RNA-seq,
however, can be cost prohibitive due to the size and complexity of
most transcriptomes, which require deep sequencing coverage to
achieve the necessary sensitivity for a reliable analysis. By combining
targeted enrichment strategies with next-generation sequencing (NGS),
a subset of transcript regions or sequences can be enriched and ana-
lyzed with the resolution required for both research and clinical applica-
tions. Here, we applied a novel RNA enrichment strategy, RNA DIRECT,
to the capture of targets commonly associated with solid tumors.
Methods: RNA DIRECT target enrichment utilizes cDNA and probe-
based hybridization to capture only desired cDNA sequences with re-
moval of off-target regions via enzymatic digestion. Targeted sequences
are then ligated to NGS platform specific adaptors and amplified by PCR.
Results: RNA converted to cDNA was used for targeted enrichment
with RNA DIRECT. Analysis of sequenced reads showed at least 97%
alignment to the transcriptome with greater than 90% aligning to
targeted regions. We also report the identification and detection of
variants and gene fusions associated with solid tumors with high
specificity and sensitivity.
Conclusion: The RNA DIRECT strategy provides a robust and cost effect-
ive method for the enrichment of targeted transcript sequences for the
identification and detection of known or novel variants and gene fusions.
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Objectives: Neuroblastomas are the most common of all malignan-
cies in infants and the most common extracranial malignancy of
childhood. With 650 new cases each year it accounts for over 15% of
childhood cancer mortality. This neuroectodermally derived malig-
nancy is most often found in the adrenal glands but can be found
throughout the body in sympathetic ganglia. Though a small number
of cases are familial (1-2%) with known genetic causes, most cases
are sporadic with little known about what causes them or what
causes the diverse outcomes of this disease.
Methods: The current study used transcriptome sequencing to locate
possible genetic mutations from a small cohort of neuroblastoma sam-
ples. The mutations were used to construct a phylogenetic tree that
demonstrated the tumor progression and predicted the outcome.
Results: Using this method a handful of associated mutations have
been found, but few effect disease outcome. In this this study we used
next generation RNA sequencing to fully sequence 249 neuroblastoma
samples. Using these samples and focusing on indel mutations we lo-
cated 1247 mutated genes that affect the favorable or unfavorable out-
come of the disease. Due to the large number of mutations, online
databases were used to identify genes associated with neuroblastomas.
Comparing these genes to our sample we found a subset of genes that
when mutated affected the survival rate of patients.
Conclusion: This study suggests the importance of a few genes that
drive the progression of neuroblastomas and determine the clinical
outcomes.
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Objectives: Was to determine the regulation of fusion gene TMPRSS2-
ERG by SFRP1 protein through negative regulation of AR
Methods
Cell culture. LNCaP, VCaP and PC3 cell lines from ATCC, were grown
in RPMI 1640 PrSC cell line was grown in Stromal Cell Basal medium
at the same conditions mentioned above. RWPE-1 cell line, was cul-
tured in medium. For hormonal treatment, RPMI without phenol red
was used it, supplemented with Charcoal Stripped serum 5%.
Viability assay. Cells were plated in 96-well plates (1–2 x 104 per
well). 48 hours after treatment, 10mL of MTT reagent was added per
well and incubated 2 hours at 37°C and 5% CO2. Next, medium was
removed and 100mL of DMSO was added to solubilize formazan
crystals. The absorbance it was readed at 575 nm wavelength.
qRT-PCR. Cells were plated in 24 well plates (1 x 105 per well, except
VCaP 2 x 105). RNA extraction it was realized with RNAeasy QUIAGEN
kit according to the manufacturer’s instructions. cDNA it was ob-
tained retrotranscription assay, it was used Revert Aid Synthesis Kit
according to the manufacturer’s instructions. To real time PCR assay,
the following taqman expression probes from Life Technologies com-
pany were used for avery target gene : GAPDH , KLK3 , AR , TMPRSS2
, ERG , TMPRSS2-ERG , SFRP1, FZD4, Wnt1, Wnt3a and LEF1.
Results: We demonstrate that TMPRSS2-ERG is deregulated by SFRP1
protein through negative regulation of androgen receptor. Further-
more, our results indicates that androgen receptor (AR), is indirectly
regulated by SFRP1 in the nucleus. We propose that the effect on fu-
sion gene, down regulates the WNT pathway, and decreases the ag-
gressive characteristics of the cell lines CaP. A negative effect on the
TMPRSS2-ERG fusion gene by SFRP1, which was reflected in a de-
crease of neoplasic cell characteristics in LNCaP and VCAP PCa cells.
Conclusion: TMPRSS2-ERG fusion gene is deregulated by SFRP1 protein
through negative regulation of androgen receptor. Androgen receptor
(AR), is indirectly regulated by SFRP1 in the nucleus. The effect on fu-
sion gene, down regulates the WNT pathway, and decreases the ag-
gressive characteristics of the cell lines CaP. A negative effect on the
TMPRSS2-ERG fusion gene by SFRP1, which was reflected in a decrease
of neoplasic cell characteristics in LNCaP and VCAP PCa cells.
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Objectives: Aggressive and potentially life-threatening prostate can-
cer often requires radical treatment. The many side effects that are
associated with such treatments underscore the importance of accur-
ate differentiation between these aggressive tumors and indolent
prostate cancer in order to reduce overtreatment. Thus, we focus on
the discovery of prognostic signatures based on changes in DNA
methylation, stratifying by disease aggressiveness.
Methods: Whole-genome bisulfite sequencing (WGBS) is cost-
prohibitive for analyzing large numbers of human cancer specimens.
Further, in order to detect subtle methylation differences between
cancer samples and in samples with low tumor purity, higher
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sensitivity is achieved through a greater read depth, further increas-
ing sequencing costs. Therefore, we utilize a targeted bisulfite se-
quencing method for the comprehensive analysis of genomic
regions relevant to cancer, comprising 84 megabases (~3% of the
human genome), covering 3.7 million CpGs, including most RefSeq
and GENCODE gene promoters, all known cancer genes, CpG islands
and their shores. Up to 100-fold read depth can be achieved on aver-
age by pooling four human prostate samples on one Illumina
HiSeq4000 lane.
Results: Of the differentially methylated regions (DMRs) we detected,
the majority is hypermethylated in the aggressive versus the indolent
prostate tumors. Most DMRs overlap a CpG island and are predomin-
antly found in or close to gene promoters, as well as the promoter
regions of long non-coding RNAs, and to a lesser extent within
gene bodies or intergenic. Often, we find strong hypermethyla-
tion of the up- and downstream CpG islands surrounding the
transcription start site (TSS), while the TSS itself stays unmethy-
lated. Furthermore, ~70% of the hypermethylated DMRs overlap
regions reported to be a bivalent promoter in various cell types
from the ENCODE project. The DMRs that can be associated with
RefSeq genes are enriched for transcription factors, and more
than half of those contain a homeodomain, such as different
members of the HOX, SOX and FOX gene families.
Conclusion: The overarching theme for DMRs called in this set of pros-
tate cancers using a targeted deep Methylation-Sequencing approach
is hypermethylation of regions within bivalent CpG islands, presenting
a prognostic methylation signature that warrants further investigation.
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Objectives: To know the frequency of the TPMT deficient alleles in
children with acute lymphoblastic leukemia and healthy subjects
from two Mexican populations
Methods: We included 813 unrelated subjects, 392 were children with
ALL and 421 were healthy subjects. Genotyping of the rs1800462,
rs1800460 and rs1142345 SNPs was performed by TaqMan assays. To
assess the differences of the genotype and allele frequencies among
groups we used the Chi-square test. Written informed consent was ob-
tained from both ALL children’s parents and healthy participants.
Results: The mutant TPMT alleles were carried by 5% of the 1636
chromosomes analyzed. Overall ALL cases, 10.2% of the subjects
were heterozygote for one of the tree variants and only 0.2% were
homozygote to the mutant allele TPMT*3A. We did not find statisti-
cally significant differences between Mestizo and Mayan ALL or con-
trols groups; however, 7.8 % of the ALL Mayan bore one TPMT
mutant allele. Moreover, 2.5% of the Maya healthy subjects were
homozygote to the null phenotype (TPMT*3A/TPMT*3A).
Conclusion: This study is the largest analysis of the TPMT mutant al-
leles performed in ALL Mexican pediatric patients [1]. Because ALL
is the leading cause of childhood cancer in Mexico [2] and homozy-
gotes TPMT deficient alleles subjects have high risk to develop se-
vere and potentially fatal hematopoietic toxicity after treatment
with standard doses of thiopurines [3]; TPMT alleles genotyping
should be performed in Mexican ALL patients. Furthermore, large-
scale genotype and phenotype correlation studies are needed to
assess the contribution of this variants in other Mexican-Amerindian
populations.
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Objectives: Alström syndrome (AS) is a progressive multi-systemic dis-
order caused by recessive mutations in the ciliary protein ALMS1.
Amongst patients with AS, we observe variability in onset and/or severity
of disease phenotypes including hearing and vision loss, obesity, hyperin-
sulinemia, hepatosteatitis, and cardiomyopathy, likely due to the pres-
ence of modifier genes. Like in patients, disease phenotypes in murine
models of AS can be modified by the genetic background. The goal of
the study was to map genetic modifier loci using an AS mouse model.
Methods: A genetrap in intron 13 of the mouse Alms1 gene was placed
onto the C57BL/EiJ and BALB/cJ inbred background strains, respectively.
To genetically dissect modifier loci of AS, we performed a phenotypic
screen of 135 Alms1Gt/Gt backcross progeny from two backcrosses:
((C57BL6/Ei X Balb/cJ)F1-Alms1+/Gt X C57BL6/Ei-Alms1+/Gt) and
(C57BL6/Ei X Balb/cJ)F1-Alms1+/Gt X Balb/cJ/Ei-Alms1+/Gt). DNA of the
backcross progeny was typed using evenly spaced microsatellite markers
throughout the genome and quantitative trait locus (QTL) analysis was
performed. Recombinational fine mapping and characterization of sub-
congenic lines was used to refine a retinal degeneration QTL on Chr. 2.
Results: QTL for body weight, plasma insulin and triglyceride levels,
alanine aminotransferase levels, hepatic steatosis, hepatic fibrosis,
and retinal degeneration were mapped to regions on five chromo-
somes. The location of a major modifier locus on Chr. 2 in which the
B6 allele protects Alms1Gt/Gt retinas from rapid photoreceptor degen-
eration was refined to a 12 Mb region. A candidate mutation in the
glutamylase TTLL9 was identified and is associated with reduced glu-
tamylation of tubulin in Balb/cJ-Alms1Gt/Gt retinas.
Conclusion: Elucidation of the genetic networks of ALMS1 may lead to
a better understanding of the role of ALMS1 in metabolic and neurosen-
sory disease and may provide novel targets for therapeutic intervention.
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Objectives: Angiotensin-converting-enzyme inhibitors (ACEIs) are
among the most commonly used drugs in the management of car-
diovascular disease. It is used as an antihypertensive and for the alle-
viation of progressive vascular injury. However, intake of ACEIs may
lead to an adverse side effect, uncomfortable dry cough that occur
in about 20-25% of patients. Although several genomic variants have
been found to be associated with ACEI-induced coughing, there are
no published data to adequately address pharmacogenetic utility
among Filipino patients. This was undertaken to determine the
prevalence and clinical association of candidate genomic variants
among Filipinos.
Methods: A case–control study involving 186 unrelated patients who
were taking ACEI for at least 6 months was done (101 males, 85 fe-
males; 62 cases, 124 controls). DNA from blood samples were ex-
tracted and were genotyped using customized Illumina Goldengate
microarray chips for 384 gene variants.
Results: Results show that allelic variants of the genes ZPR1, ADAMTS7,
CTB-129P6.7 and LOC157273 are significantly associated with ACEI-
induced coughing (OR: 2.34, 3.120, 2.49 and 2.64, respectively, p<0.01).
Using genotypic modeling, ZPR1 shows a dominant trend, while
ADAMTS7 and CTB-129P6.7 manifest genotypic patterns (Cochran-
Armitage test, p<0.01). Further, an intergenic loci in chromosome 4 is
also significant. Interestingly, using logistic regression, in addition to
ZPR1, ADAMTS7 and CTB-129P6.7, eight variants located proximal to
each other in the X chromosome have been associated with the ACEI-
induced coughing.
Conclusion: The study presents possible pharmacogenetic markers
for Filipinos, as well as genomic regions of interest that may further
shed light on the mechanisms of ACEI-induced coughing.
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Objectives: Mutations in GARS (glycyl tRNA synthease) cause auto-
somal dominant Charcot-Marie-Tooth disease type 2D (CMT2D).
Thirteen GARS variants have been previously linked to CMT2D. Re-
cently, diagnostic whole exome sequencing revealed heterozygos-
ity for a novel, de novo, 12 base-pair deletion in exon 8 of GARS
(c.894_904del12) in a one year-old female showing symptoms in-
cluding hypotonia and weakness. This variant causes an in-frame
deletion of four amino acids (E299-302Qdel, referred to as “ΔETAQ”)
within the catalytic domain of the enzyme and is thus likely dele-
terious. To validate ΔETAQ as the causative mutation, we are cur-
rently engineering a “humanized” mouse model in which both the
normally functioning human sequence of exon 8 and the mutant
ΔETAQ variant sequence of exon 8 have been introduced into the
mouse genome.
Methods: We have successfully engineered a mouse that expresses the
wild-type human sequence of GARS exon 8 using CRISPR/Cas genome
editing technology and are currently engineering a mouse that will ex-
press the mutant sequence. Once both strains are verified we will cross
them to produce a compound heterozygote with the same putatively
pathogenic DNA sequences as the patient (GarsΔETAQ/+). Once
established as stocks, the GarsΔETAQ/+ mice will be evaluated for fea-
tures of neuropathy observed in other established mouse models
of GARS-linked CMT2D. The GarsΔETAQ mice will also provide a hu-
manized disease model for preclinical studies. Previous studies pre-
dict that knockdown of mutant GARS should be therapeutically
beneficial for patients with CMT2D, provided wild type GARS is
preserved. Therefore, we developed a gene therapy strategy that
involves the allele-specific knockdown of mutant GARS transcripts
by virally delivered RNAi. RNAi vectors designed to target the ΔETAQ
variant as well as other confirmed CMT2D-linked GARS variants
have been developed and tested in vitro for knockdown efficacy
and specificity.
Results: The results of our in vitro studies confirm that we have de-
veloped several RNAi sequences that specifically target several GARS
variants but not wild type GARS.
Conclusion: Success with this novel gene therapy approach will pro-
vide a promising avenue for treatment of CMT2D and other domin-
antly inherited neuromuscular diseases.
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Objectives: Human induced pleuripotent stem cells (hiPSC) are a
promising source for chondrogenic stem cells. Sequential differenti-
ation of hiPSC provides a platform for dissecting the molecular path-
ways associated with chondrogenesis in vivo and could reveal targets
for better control of chondrocyte fate for cartilage repair applications.
The aim of this study was to use next generation sequencing (NGS)
to investigate the transcriptome and the methylome of chondrogenic
hiPSCs.
Methods: The hiPSC line (C19) was derived through reprogramming
of human dermal fibroblasts using viral vectors expressing Oct4,
Sox2 and Klf4. A protocol of sequential growth factors including Acti-
vin A, FGF2 and BMP4 was used to drive the formation of chondro-
progenitors directly from hiPSC colonies. The chondrogenic hiPSCs
were characterised exhaustively by tissue engineering, histochemical
analysis and biochemical analysis. The transcriptome of undifferenti-
ated hiPSCs, hiPSC derived chondrocytes and native chondrocytes
was interrogated utilizing RNASeq on the SOLiD 5500 XL platform
where the polyA fraction was sequenced at a coverage level of at
least 25 million reads.
Results: Differential gene expression revealed the induction of sev-
eral collagen genes including type 1 to type 12, type 14 and type 18
during transition from the pluripotent state to the chondrogenic
state (Fig. 7). Collagen regulatory genes such as PCOLCE which drives
the endopeptidase cleavage of procollagen as well as regulators of
collagen glycosylation were upregulated. The expression of various fi-
broblasts growth factors (FGFs) including FGF11, FGFR2 and insulin
growth factor2 (IGF2) was upgregulated as well as the Wnt induced
secreted protein, WISP2. Mitotic genes were downregulated in de-
rived and differentiated chondrocytes. Integrated methylome and
transcriptome analysis revealed the step-wise differentiation process.
Conclusion: NGS analysis demonstrated the recapitulation of early
events in cartilage development during hiPSC chondrogenesis. The
upregulation of many members of the collagen family indicate the
intricate nature of collagen expression during chondrogenesis. Fur-
ther analysis of nonchondrogenic targets may reveal novel pathways
for controlling the fate of chondrogenic hiPSCs.
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Objectives: Next generation sequencing (NGS) can be used to iden-
tify clinically relevant variants for accurate diagnosis, prognostic risk
stratification, and identification of therapeutic targets for genotype-
matched trials in cancer. Our objective was to design methods for ef-
ficient prioritization of variants for interpretation and reporting. We
describe a triaging algorithm to identify clinically relevant variants
from tumour-only analysis of NGS in hematological malignancies.
Methods: Blood or bone marrow DNA from 260 patients recruited in
the Princess Margaret Cancer Centre’s Advanced Genomics in
Leukemia (AGILE) trial were profiled using the 54 gene TruSight Mye-
loid Sequencing Panel (Illumina). Variants were called using the Illu-
mina MiSeq Reporter (MSR) software. Data were uploaded into a
commercially available tool, Cartagenia Bench NGS, for filtering and
analysis.
Results: Of all variants detected by NGS (median 427, range 338–643
variants/case), 35% (median 150, range 125–172 variants/case)
passed all MSR quality criteria. Applying a variant allele frequency
threshold refined the data to 7.4% of the original dataset (median
30, range 16–48 variants/case). Reporting was restricted to well-
covered, exonic nonsynonymous, intronic splice site, and known
pathogenic synonymous variants, resulting in a median of 4 variants/
case for manual review (range 0–13). When combined with our data-
set of >600 interpretations across 8 hematological malignancies, this
approach enabled rapid review and interpretation of previously
known variants, and an effective system to prioritize novel variants in
order of clinical actionability (Sukhai et al., 2015). We excluded vari-
ants with high germline population frequencies (median 50, range
42–62 variants/case) through the use of multiple reference popula-
tion databases.
Conclusion: We describe our approach to prioritize NGS derived vari-
ants, based on data quality, functional effects, allele frequency, cover-
age depth, and coding effects. This approach iteratively utilizes our
lab-developed variant knowledge base, and enables us organize and
use variant interpretations to generate clinical reports.
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Objectives: NCBI provides many resources for evaluating and declar-
ing evidence of pathogenicity for an increasing number of human
sequence variants. Primary details about a genetic test’s analytical
validity and clinical utility are reported in the Genetic Test Repository,
and evidence for inferences of variant pathogenicity are summarized
in ClinVar. NCBI has developed several tools that integrate these
high level records with the more basic factual data describing them
as population level variants (dbSNP/dbVar), and deeper still as
individual-level observations with called genotypes (the NCBI Geno-
type Server), phenotypes (dbGaP), whole genome/exome sequences
(SRA) and finally as positions on the reference genome (GRC human
reference assemblies).
Methods: Traversing the connections between variant-level records,
e.g. GTR, ClinVar and dbSNP, and individual-level data (e.g. geno-
types, sequences, samples, and phenotypes) is a computationally in-
tensive activity, and NCBI has developed several new services to pre-
compute these relationships and permit users to quickly move from
summary records to individual level data.
Results: This presentation will introduce several of these services in-
cluding allele registry, the ClinVar beacon search, and the dbGaP
genome browser with particular emphasis on how users can access
and review individual level data for clinical variants or ad hoc gen-
omic positions of particular interest.
Conclusion: Examples of use include the review of ClinVar records by
expert panels, identify research into the existence of specific se-
quence alleles, automatic notification when new data for specific po-
tential alleles of interest are submitted to NCBI, confirmation of
variant properties during manuscript review, and research in general
questions of human genetic architecture.
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Objectives: Genetic variation analysis plays an important role in elu-
cidating the causes of various human diseases. The drastically re-
duced costs of genome sequencing driven by next generation
sequence technologies now make it possible to analyze genetic vari-
ations with hundreds or thousands of samples simultaneously, but
with the cost of ever increasing local storage requirements. The tera-
and peta-byte scale footprint for sequence data imposes significant
technical challenges for data management and analysis, including
Fig. 7 (abstract P34).
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the tasks of collection, storage, transfer, sharing, and privacy protec-
tion. Currently, each analysis group must download all the relevant
sequence data into a local file system before variation analysis is initi-
ated. This heavy-weight transaction not only slows down the pace of
the analysis, but also creates financial burdens for researchers due to
the cost of hardware and time required to transfer the data over typ-
ical academic internet connections.
Methods: To overcome such limitations and explore the feasibility
of analyzing control-accessed sequencing data in cloud environ-
ment while maintaining data privacy and security, here we intro-
duce a cloud-based analysis framework that facilitates variation
analysis using direct access to the NCBI Sequence Read Archive
through SRA Toolkit, which allows the users to programmatically ac-
cess data housed within SRA with encryption and decryption cap-
abilities and converts it from the SRA format to the desired format
for data analysis.
Results: A customized machine image (ngs-swift) with preconfigured
tools, including SRA Toolkit and NGS Software Development Kit, and
resources essential for variant analysis has been created for instanti-
ating an EC2 instance or instance cluster on Amazon cloud. Perform-
ance of this framework has been evaluated using dbGaP study
phs000710.v1.p1, and compared with that from traditional analysis
pipeline, and security handling in cloud environment when dealing
with control-accessed sequence data has been addressed. We dem-
onstrate that with this framework, it is cost effective to make variant
calls without first transferring the entire set of aligned sequence data
into a local storage environment.
Conclusion: This direct data access approach using NCBI SRA Toolkit
from cloud for next generation sequencing analysis is more cost-
effective in terms of time and disc spaces being used for the analysis,
and thus will accelerate variation discovery using control-accessed
sequencing data.
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Objectives: Liver is the primary organ responsible for drug metaboli-
zation process. Many currently and normally used drugs could affect
the liver adversely in any combination of the reactions described.
Gene expression profiling can be used to identify the mechanisms
that underlie the potential toxicity of chemicals. This technology has
also been applied to identify biomarkers of toxicity to predict poten-
tial hazardous chemicals. We propose a strategy that allows to com-
bine models (Hu, Rat), protocols (iVV, iVT), dosages (None, Low,
Med, High) and time points to correlate gene profiles to levels of
toxicity of 131 compounds, mainly medical drugs and their effect in
the liver.
Methods: The strategy involves differential expression by group con-
trasts or ranking genes based on absolute or relative amounts of
change over time as a function of the drug concentration in relation
to their replicate variances. Once genes are classified, a series of
class discovery methods are applied to identify and analyze pat-
terns of chemical structure, gene profiles over time or gene pro-
files by compound dose. We used the Japanese toxicogenomics
project, data contains a collection of 17,657 AffymetrixTM microar-
rays from human in vitro and animal samples. Data are pre-processed
in the R statistical environment using a collection of libraries from
Bioconductor.
Results: Due to the dynamic nature of the data, we implemented
a time course analysis for each species in all dosages and for all
compounds. For every subset, genes are classified according to a
multivariate empirical Bayes statistic for replicated microarray
time course data. Genes were ranked based on large absolute or
relative amounts of change over time as a function of the drug
concentration in relation to their replicate variances. A hierarch-
ical clustering analysis to identify patterns of gene profiles was
performed. Genes were selected based on top ranking according
to their MB statistic.
Conclusion: Our approach involves the development of a pipeline
that involves involves analyses that are hypothesis free or hypothesis
driven. Hepatotoxicity caused by drugs, in particular idiosyncratic re-
actions, is a major challenge to the pharmaceutical industry and phy-
sicians. The application of new technologies, such as genomics,
offers the potential to identify risk factors and clarify the pathogen-
esis of idiosyncratic hepatotoxicity. Even with these technologies the
data mining process is the real challenge.
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Objectives: Bioinformatics analyses have increasingly become com-
pute intensive processes, with lowering costs of data production and
increasing numbers of samples. Each laboratory spends time creating
and maintaining a set of pipelines, which may not be robust, scalable,
or efficient. Further, the existence of different computing environments
across institutions hinders both collaboration and the portability of ana-
lysis pipelines.
Methods: Flowr is a robust and scalable framework for designing and
deploying computing pipelines in an easy-to-use fashion. It implements
a scatter–gather approach using computing clusters, simplifying the
concept to the use of five simple terms (in submission and dependency
types). Most importantly, it is flexible, such that customizing existing
pipelines is easy, and since it works across several computing environ-
ments (LSF, SGE, Torque, and SLURM), it is portable.
Results: Ultraseq; Using flowr’s framework we have created a flexible
pipeline for somatic variant calling. This aligns raw reads, splitting
the processing across multiple nodes of a computing cluster. Results
are gathered, creating a merged bam; which is then split according
to the contigs in the genome. Further steps including de-duplication,
indel-realignment and base-quality recalibration and variant calling
are performed at the contig level, using a scatter–gather approach.
This enables complete processing of a typical whole-exome in about
two hours, and whole-genome in a few hours (depending on the li-
brary size).
Conclusion: Flowr follows the “design once” principle, enabling
the user to develop robust, portable pipelines that can be run on
a host of computing platforms. Further, the same pipeline can be
run on a local machine, computing cluster, or cloud-based envir-
onment. With automatic logging of each step and the preserva-
tion of the exact commands run to produce the output, the
system allows users to generate an easy-to-use, efficient, and re-
producible analysis pipeline. Ultraseq provides a fast and robust
and modular pipeline for somatic variation calling. This enables
users to easily add new tools and methods are they are released,
and possibly share with other users in a format, which is robust,
efficient and portable.
Availability: http://docs.flowr.space
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Objectives: Analysis of large cohort genomic data is a complex task,
typical bioinformatics approaches use collections of scripts and R
code, this becomes difficult to manage as sample numbers grow to
10’s of thousands and file sizes grow to terabytes. We applied “Big
data” technologies to the analysis of 578 HI-seq X whole genomes
(WGS) and 10,913 exomes (WES), in both cases we QC’d and inte-
grated billions of variant calls from Atlas and GATK to provide con-
cordant and consensus genotypes.
Methods: Raw variant data was pre-processed to produce key value
pairs; keys representing variants and values representing sample spe-
cific data stored as JSON. Using a modest Hadoop test cluster (88
cores 512 Gb memory 7tb disk), we imported the data into Hbase ta-
bles. WGS data was stored as 578 columns, one column per sam-
ple.WES data was stored as a single column due to the large number
of samples.
QC and analysis were performed by first building normalised sum-
mary tables in Hive, this process required a full Hbase table scan and
took several hours to complete. However, once the data was proc-
essed, we were able to perform rapid analysis (minutes) on both the
WGS and WES data sets using identical SQL queries regardless of
how the underlying data was structured.
In this way we were able to perform QC filtering such as Ti/Tv, mapp-
ability, monomorphic sites, missingness rates and Hardy-Weinberg
on both the variant and sample level, easily excluding/including sub
cohorts for different tests.
Results: Our queries were verified by comparison to 2 independ-
ent sets of QC statistics for the 578 WGS samples, once we had
confirmed that we could exactly reproduce these numbers we
were then able to quickly apply the same QC steps to the much
larger 10,913 WES data set. Because the tests could be per-
formed rapidly it became practical to iteratively tune parameters,
in this way we were able to modify the Atlas genotype boundar-
ies so as to maximise the numbers of concordant genotypes
with GATK.
Conclusion: By leveraging the power of map-reduce and the rich
ecosystem of tools around Hadoop we were able to streamline the
analysis of these large genomic data sets, rapidly processing billions
of genotypes using simple SQL queries to provide accurate, reprodu-
cible QC statistics without the need to track and manage thousands
of files.
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Objectives: To identify genome-wide transcription start site activ-
ities in various mammalian cells, a worldwide collaborative project,
FANTOM5 (Functional Annotation of Mammalian Cells 5) was orga-
nized. In this project, diverse range of mammalian samples (~2000
for human and ~1200 for mouse, including primary cells, cancer cell
lines, tissues, and transiting cells in time courses) was profiled to
obtain promoter-level transcriptional atlas using high-throughput
sequencers. To provide this large-scale data collection to the scientific
community, we developed an integrated web resource, the FANTOM5
web resource.
Methods: To support various sort of inspections and analyses, the
web resource contains several tools. SSTAR (Semantic catalogue of
Samples, Transcription initiation And Regulators) provides a wide
range of analysis results as well as detailed information of individual
samples; ZENBU, a data integration, data processing, and expression
enhanced visualization system designed for big data genomics pro-
jects, provides interactive way to inspect the entire promoter activ-
ities measured in FANTOM5 interactively; and Table Extraction Tool
(TET) provides an easy-to-use interface to download subsets of the
overall FANTOM5 expression table in an efficient way. A BioMart in-
stance and a track hub for UCSC genome browser enable us to ac-
cess our TSS resources with widely used interfaces. Furthermore,
PrESSto provides an interface to browse human enhancers identified
in the FANTOM5 project, and Biolayout enable us to visualize bio-
logical states in a three dimensional expression space with inter-
active interface.
Results: The web resource is accessible from the FANTOM5 portal
page: http://fantom.gsc.riken.jp/5/.
Fig. 8 (abstract P40).
Table 2 (abstract P41). Example of summary statistics comparing Atlas
genotype calls with differing allele fraction thresholds with GATK calls.
Genotype GATK ATLAS
(ORIGINALS)
ATLASDP>=
100.25<0/
1>0.75
ATLASDP>=
100.1<0/
1>0.9
ATLASDP>=
100.1<0/
1>0.75
0/0 1,793,394,356 1,788,668,240 1,778,668,240 1,778,668,240 1,778,668,240
0/1 138,744,203 69,153,666 112,165,710 147,763,797 124,056,267
1/1 79,407,733 60,398,312 73,417,546 49,710,016 73,423,295
Het / hom 1.75 1.14 1.53 2.97 1.69
Total 2,011,546,292 1,908,220,218 1,964,251,496 1,976,142,053 1,976,147,802
Concordant
Genotypes
GATK +
ATLAS
(ORIGINALS)
GATK +
ATLAS
(0.25<0/
1>0.75)
GATK +
ATLAS
(0.1<0/
1>0.9)
GATK +
ATLAS
(0.1<0/
1>0.75)
0/0 914,737,638 1,021,734,445 1,050,682,661 1,049,337,470
0/1 39,133,931 72,422,398 74,278,418 75,570,661
1/1 17,017,045 45,077,505 33,993,884 45,368,697
Het/hom 2.30 1.61 2.19 1.67
Total 970,888,614 1,139,234,348 1,158,954,963 1,170,276,828
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Conclusion: The resource is continuously updating, for example, the
data remapped to the recent genomes was added. The FANTOM5
web resource is a gateway to access the large expression atlas in
mammalian and we describes our challenges to provide large-scale
genomic data to the scientific community from multiple aspects.
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Objectives: For studies such as the Alzheimer’s Disease Sequencing
Project and the CHARGE Consortium, disease complexity manifests
as data heterogeneity, requiring informatics that can additively scale
to thousands of samples and analytics that go beyond identifying
small variants in capture data. Specifically, whole-genome sequen-
cing (WGS) can assess large, complex genomic variation in both cod-
ing and non-coding regions. At scale, the challenge of evaluating
these structural variants (SVs) becomes the “N+1” problem of incre-
mentally adding samples without having to perpetually reevaluate
petabytes of population read data stored in BAM files.
Methods: The Biograph Analysis Format (BAF) is a novel method of
indexing NGS data that allows rapid, at-scale queries by coordinate
and genomic sequence. A BAF of HiSeq X 30x WGS data is 8.3 Gb,
95% smaller than the corresponding BAM. Generated from the BAM
in 14 hours, the BAF can be queried up to one million times a sec-
ond. Querying by both coordinate and sequence is particularly ap-
plicable to SV typing: the presence and genotype of an SV can be
evaluated using coverage, mismapped reads, and characteristic se-
quences. This flexibility allows BAF queries to capture SV diversity.
Together, fast querying of small files with reasonable compute re-
quirements provides an N+1 solution.
Results: To evaluate the BAF, we indexed the HS1011 reference
genome sequenced with 60x coverage on the HiSeq X. The HS1011
individual has previously been characterized for SV content, identi-
fying ~10,000 high-confidence SVs from ~30,000 putative sites.
These sites were BAF-queried in less than 60 seconds. SV-typing
these sites across 10,000 HiSeq X WGS samples in BAF would re-
quire less than 100 TB, 166 CPU hours, and 2.5 total hours. Because
the BAF can be batched across individuals, query time grows less
than linearly with the number of individuals.
Conclusion: We will describe how the BAF API allows users to query
SV data, how these queries inform SV typing, and how BQF typing
performs on a pilot set of 100 30x HiSeq X samples from a disease
cohort, providing counts and allele frequencies for multiple SV types.
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Objectives: Glutathione S-transferases (GSTs) play a major role in the
detoxification of various compounds. Similarly, human sulfotransferases
(SULTs) are involved in the metabolism of many drugs, xenobiotics,
neurotransmitters and hormones. Polymorphic variants in GST and
SULT1A1 genes were reported for different populations. The objectives
of this study were to determine the frequencies of GSTM1 and GSTT1
null genotypes, and the genotype and allele frequencies of SULT1A1
(G638A) gene polymorphism in the Sudanese population.
Methods: GST genotyping was carried out using multiplex PCR while
SULT1A1 genotyping was done using PCR-RFLP. Study population in-
cluded 114 (GST genotyping) and 142 (SULT1A1 genotyping) unre-
lated healthy Sudanese subjects.
Results: The prevalence of GSTM1 and GSTT1 deletion homozygosity
were 54.7% and 42.1%, respectively. The genotype frequencies of
SULT1A1 gene polymorphism showed that 40.8% of Sudanese were
homozygous for the GG genotype, 50.7% were heterozygous for the
GA genotype and 8.5% were homozygous for the AA genotype. The
frequencies of the SULT1A1*1 and SULT1A1*2 alleles in the SULT1A1
Gene were found to be 0.66 and 0.34, respectively. There are no sig-
nificant differences in allelic distribution of GSTM1 gene between the
Sudanese and other ethnic groups except for sub-Saharan Africans.
As regards the allelic distribution of GSTT1 gene, the Sudanese
population is similar to sub-Saharan Africans but significantly differ-
ent from Europeans. Combined analysis of both genes revealed that
24.6% of Sudanese harbor the deleted genotype of both genes and
it is the highest reported so far for an Arab and African population.
The frequency of the SULT1A1*2 allele did not differ significantly
from Caucasians and African-Americans, but it was much higher
than in Asians.
Conclusion: This is the first study that addresses polymorphism of
GST and SULT1A1 genes in Sudanese. We provide a reference data-
base of allelic frequencies of the genotypes of these genes among
Sudanese.
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Objectives: The frequency distribution of pharmacogenomics markers
across the populations in the worldwide can differ in magnitude or be
absent depending on the population being assessed. The CYP3A5*3
(rs776746) is the most frequent and well-studied variant allele of
CYP3A5. This polymorphism have been related to the guidelines re-
garding the use of pharmacogenomic tests in dosing of immuno-
suppressive Tacrolimus drug published in Clinical Pharmacology
and Therapeutics by the Clinical Pharmacogenetics Implementation
Consortium (CPIC). The CYP3A5*3 genotype is polymorphic in sev-
eral continental and large populations, for example the minor allele
frequency (MAF) of rs776746 marker in Europeans and Africans pop-
ulations is opposite, while A allele is the minor (0.036) for Europeans G
allele is the minor (0.15) in Africans. However, this pharmacoge-
nomic marker is not well-studied in the admixed and Native American
populations. The objective in this study is evaluate the distribution of
allele frequencies for the CYP3A5*3 variant across the admixed and Na-
tive American (Mexican) populations.
Methods: Genotypes for rs776746 from the Mexican Genome Diver-
sity Project database were analyzed. Allele frequencies were calcu-
lated for 4 Native American-Mexican populations located in north,
central and southwest Mexico territory plus 370 Mexican mestizos
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and 60 European, 60 African, 90 East Asian from the HapMap project.
The Fst statistic was analyzed as measure of the degree of genetic
differentiation pairwise populations.
Results: Extreme genetic differentiation among HapMap popula-
tions for was observed for CYP3A5*3 (rs776746) as one would ex-
pect, particularly for the comparisons of African and European
ancestry populations. However, the largest Fst statistic and allele fre-
quencies values was found among Native Americans. For example,
the allele frequency of CYP3A5*3 allele is more than 6-fold higher in
Tepehuanes (0.43) than Zapotecas (0.07) with Fst value of 0.1746
(largest divergence).
Conclusion: We identified novel CASR variants that have a potential
to be related to serum calcium levels in Korean population. Inter-eth-
nic differences were suggested in some associated SNPs. Given the
significant role played by calcium in many diseases and cell signal-
ing, further studies with more East Asian subjects or meta-analyses
on them may enable validation of our results and identification of
novel genetic loci associated with serum calcium levels.
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Objectives: Blood cell counts and erythrocyte indices are clinically
important indicators of a variety of disease states. The ability to de-
tect and include novel rare variants in gene-based tests is best ac-
complished via sequencing.
Methods: In order to identify novel genes influencing hematologic
traits, we analyzed whole exome sequencing data in 15,459 partici-
pants of 6 population-based cohort studies for 13 traits in European
descent (EU) and African Americans (AA), analyzed together and sep-
arately, in fixed-effects meta-analyses. We analyzed variants individu-
ally and aggregated functional and loss-of-function (LOF) variants
with MAF<5% within genes using SKAT and T5 burden tests. CRISPR/
Cas9 genome editing was performed to functionally follow up a rep-
licated novel finding.
Results: Discovery phase associations identified 4 novel gene-based
results and 3 novel single variants meeting exome-wide Bonferroni
corrected thresholds (P<2.6x10−6 and P<1.6x10−7). Rare functional
variants in MYOM2 were associated with mean corpuscular hemo-
globin concentration (SKAT PEU+AA=2.2x10
−6). In EUs, rare variants in
MRPL43 were associated with hemoglobin (T5 PEU=1.2x10
−6). LOF
Variants in MMACHC were associated with hemoglobin (SKAT PEU=
1.3x10−6). MMACHC regulates vitamin B12 metabolism and known
variants cause a Mendelian syndrome including anemia. In AAs, rare
functional variants in ACTN4 were associated with mean corpuscular
volume (SKAT PAA=1.5x10
−6). ACTN4 variants were previously associ-
ated with focal segmental glomerulosclerosis of the kidney. Among
the single variant tests, we found low-frequency variant rs9656446
(MAF=0.03, PEU+AA=1.5x10
−7) in AGBL3 to be associated with basophil
count. A common variant in CPS1 (rs1047891, MAF=0.33, PEU+AA=
5.7x10−8) was associated with platelet count. We also identified an
association of platelet count with a low-frequency (MAF=0.009)
synonymous variant (rs150813342, PEU=4.7x10
−8) in GFI1B, a gene
known to cause gray platelet syndrome. In silico algorithms predict
rs150813342 to affect exon 5 splicing. Replication in up to 52,024 in-
dividuals were significantly associated with lower platelet count for
CPS1 rs1047891 (MAFEU+AA=0.328, P=1.02x10
−4) and GFI1B rs150813342
(P=5.71x10−21).
Conclusion: In this exome sequencing study, we identified a novel
low frequency loci. We demonstrate an alternative splicing mechan-
ism by which the GFI1B rs150813342 variant suppresses formation of
a GFI1B isoform that preferentially promotes megakaryocyte differen-
tiation and platelet production.
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Table 3 (abstract P46). Genetic differentiation among Native and
admixed Mexican populations
POP1_
name
POP2_
name
POP1_
freqrs776746
POP2_
freqrs776746
Fst
(Pop1vsPop2)
ZAPOTECAS CEU(hapmap) 0.07143 0.036 0.0062
ZAPOTECAS YRI(hapmap) 0.07143 0.845 0.6026
ZAPOTECAS JPT+CHB 0.07143 0.2921 0.0819
ZAPOTECAS MEXICAN
MESTIZOS
0.07143 0.2263 0.0473
ZAPOTECAS MIXTECOS 0.07143 0.23333 0.0507
ZAPOTECAS MAYAS 0.07143 0.1481 0.0150
ZAPOTECAS TEPEHUANES 0.07143 0.4348 0.1746
MAYAS CEU(hanmap) 0.1481 0.036 0.0376
MAYAS YRI(hapmap) 0.1481 0.845 0.4857
MAYAS JPT+CHB 0.1481 0.2921 0.0302
MAYAS MIXTECOS 0.1481 0.23333 0.01188
MAYAS TEPEHUANES 0.1481 0.4348 0.0995
MAYAS MEXICAN
MESTIZOS
0.1481 0.2263 0.0100
TEPEHUANES CEU(hanmap) 0.4348 0.036 0.2209
TEPEHUANES YRI(hapmap) 0.4348 0.845 0.1826
TEPEHUANES JPT+CHB 0.4348 0.2921 0.0220
TEPEHUANES MIXTECOS 0.4348 0.23333 0.0456
TEPEHUANES MEXICAN
MESTIZOS
0.4348 0.2263 0.0456
MIXTECOS CEU(hanmap) 0.23333 0.036 0.0835
MIXTECOS YRI(hapmap) 0.23333 0.845 0.3764
MIXTECOS JPT+CHB 0.23333 0.2921 0.0045
MIXTECOS MEXICAN
MESTIZOS
0.23333 0.2263 0.001
MEXICAN
MESTIZOS
CEU(hanmap) 0.2263 0.036 0.0795
MEXICAN
MESTIZOS
YRI(hapmap) 0.2263 0.845 0.3847
MEXICAN
MESTIZOS
JPT+CHB 0.2263 0.2921 0.0056
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Objectives: African Americans experience disproportionately higher
prevalence of type 2 diabetes and related risk factors. Little research
has been done on the association of ADIPOQ gene on type 2 dia-
betes, plasma adiponectin, blood glucose, HOMA-IR and body mass
index (BMI) in African Americans. The objective of our research was
to assess such associations with selected SNPs. The study included a
sample of 3,020 men and women from the Jackson Heart Study who
had ADIPOQ genotyping information.
Methods: Unadjusted and adjusted regression models with covari-
ates were used with type 2 diabetes and related phenotypes as the
outcome stratified by sex. There was no association between se-
lected ADIPOQ SNPs with type 2 diabetes, blood glucose, or BMI in
men or women.
Results: There was a significant association between variant
rs16861205 and lower adiponectin in women with minor allele A in
the fully adjusted model (β(SE) p = -.13(0.05), 0.003). There was also
a significant association with variant rs7627128 and lower HOMA-IR
among men with minor allele A in the fully adjusted model (β(SE) p
= -0.74(0.20), 0.0002).
Conclusion: These findings represent new insights regarding the as-
sociation of ADIPOQ gene and type 2 diabetes and related pheno-
types in African American men and women.
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Objectives: Calcium is a universal intracellular messenger that has an
important role in controlling various cellular processes. In this study,
we attempts to evaluate the genetic polymorphisms that affect
serum calcium levels in Korean population through a two-stage gen-
ome-wide association study with the sample of 8642 unrelated Ko-
reans (4558 for discovery and 4093 for replication).
Methods: Study subjects were selected from an ongoing population-
based study known as the Korean Genome and Epidemiology Study
(KoGES) and genotyped using the Affymetrix Genome-Wide Human
SNP Array 5.0. We applied standard quality control parameters such
as SNP call rate >95%, minor allele frequency >5% and HWE P>0.001.
After this quality control process, genotypes of 4558 individuals for
1219546 autosomal SNPs were used for stage 1 association analysis.
Results: Using SNP arrays, we discovered 963 associated SNPs in
stage 1, and replicated 105 SNPs among them in stage 2. We exam-
ined them in a combined set of stage 1 and 2 samples and observed
that 65 SNPs were significantly associated with serum calcium levels.
Among them, rs13068893 in the CASR gene showed the strongest
significance (P=3.85×10−8). Considering the high allele frequency
and significance level of the rs13068893 C>G in the CASR gene, this
SNP may have a key role in regulating the serum calcium level. We
also successfully replicated the four loci (CASR, CSTA, DGKD and
GCKR) using our data set that have been previously reported to be
significantly associated with calcium levels in Europeans and Indians.
Conclusion: In this exome sequencing study, we identified a novel
low frequency loci. We demonstrate an alternative splicing mechan-
ism by which the GFI1B rs150813342 variant suppresses formation of
a GFI1B isoform that preferentially promotes megakaryocyte differen-
tiation and platelet production.
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Objectives: To infer the histories of complex admixture, two import-
ant challenges stand out with methods based on the admixture-in-
troduced linkage disequilibrium (LD): getting rid of the effect of
confounding LD (CLD) brought by source populations and fitting LD
decay induced by admixture. In previous studies, the decay curve of
weighted LD between pairs of sites whose genetic distance were big-
ger than a certain starting distance was fitted by single or multiple
exponential functions, for the inference of single- or multiple-wave
of admixture.
Methods: In this study, we developed a new LD based algorithm,
named MALDmef, to date the multiple-wave admixtures. Different
from previous software, MALDmef takes advantage of derived source
populations to reduce the effect of CLD and fits the remaining
weighted LD decay curves with hundreds of exponential functions.
Results: The performance of MALDmef was evaluated by simulation
and it was shown to be more accurate than MALDER, a state-of-the-
art LD based method that was recently developed for similar pur-
poses, under various admixture models. We further applied MAL-
Dmef to analyzing genome-wide data from the Human Genome
Diversity Project (HGDP) and the HapMap Project. Interestingly, we
were able to identify more than one admixture events in several
populations, which have yet to be reported. For example, two major
admixture events were identified in Xinjiang Uyghur, occurring
around 27–30 generations ago and 182–195 generations ago, re-
spectively. In an African population (MKK), three recent major admix-
tures occurring 13–16, 50–67, and 107–139 generations ago were
detected.
Conclusion: Our method is a considerable improvement over other
current methods and further facilitates the inference of the histories
of complex population admixtures.
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Objectives: Recent technical and methodological advances have
greatly expanded genome-wide association studies (GWAS). The advent
of low-cost whole-genome sequencing facilitates high-resolution vari-
ant identification, and the development of linear mixed models (LMM)
allows improved identification of putatively causal variants. While es-
sential for correcting false positive associations due to population
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stratification, LMMs have been restricted to numerical variables. How-
ever, phenotypic traits in association studies are often categorical,
coded as binary case–control or ordered variables describing disease
stages. Furthermore, optimally integrating the results of prior studies
remains a methodological challenge.
Methods: To address these issues, we have devised a method for
genomic association studies that implements a generalized linear
mixed model (GLMM) in a Bayesian framework, called Bayes-GLMM.
Bayes-GLMM has four major features: support of categorical variables;
cohesive integration of previous GWAS results for related traits by
Bayesian modeling; correction for sample relatedness by mixed mod-
eling; and model estimation by both MCMC sampling and maximal
likelihood estimation.
Results: To demonstrate our method, we applied Bayes-GLMM to the
whole-genome sequencing cohort in the Alzheimer’s Disease Se-
quencing Project (ADSP). This study contains 576 individuals distrib-
uted across 111 families, each with Alzheimer’s disease diagnosed at
four confidence levels. The profound population structure in these
data required a mixed model approach, and the categorical trait ne-
cessitated a generalized model.
Conclusion: In summary, this work provides the first implementa-
tion of a flexible, generalized mixed model approach in a Bayesian
framework.
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Objectives: Hearing loss is one of the most common afflictions in the
world affecting about one in every 1000 newborns (Petersen and
Willems 2006). Genetic factors are estimated to be the underlining
cause of more than half of the hearing loss cases. The majority of
hereditary hearing loss cases is not associated with syndromes
(nonsyndromic hearing loss; NSHL) which can be transmitted in an
autosomal recessive, autosomal dominant or X-linked modes of in-
heritance (Petersen and Willems 2006). At least half of the hereditary
NSHL cases are caused by mutations in the GJB2/CONNEXIN26
gene (Hereditary Hearing Loss Home Page, http://webh01.ua.ac.be/
hhh/). However, the contribution of GJB2 mutation to NSHL in the
Kingdom of Saudi Arabia is minimal (Al-Qahtani et al. 2009) where
the rate of children affected with sensineuronal hearing loss was
estimated to be approximately 26 children out of 1000 (Bafaqeeh
et al. 1994). NSHL can be caused by mutations affecting any one
of over 80 deafness loci identified so far making NSHL a very
heterogenous trait and complicates diagnosis and genetic counseling
(Hilgert et al. 2009).
Methods: The recent advancements in targeted sequencing tech-
nologies have made it feasible to sequence multiple genes at a rea-
sonably low cost. Therefore we have designed a targeted sequencing
panel using the Ampliseq technology to amplify and sequence 84
genes known to cause NSHL. Genes were selected and custom
primers were designed and manufactured through the Ampliseq por-
tal (http://ampliseq.com).
Results: The design resulted in a coverage of 97.42% generating
2697 amplicons with a size range of 125–275 bp in two pools and
generating 500.44 kb of DNA sequence.
Conclusion: This panel, which we termed OtoScan will be a useful
front line genetic screening tool that will speed up the identification
of many genetic causes of hereditary deafness in the Kingdom of
Saudi Arabia.
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Objectives: Enhancers are cis-regulatory elements that regulate gene
expression in the control of cell type-specific functions, developmen-
tal fate and evolution. Recent studies revealed the importance of
enhancer misregulation for the pathogenesis of certain diseases in-
cluding cancer through point mutations in either regulatory elements
or factors modulating enhancer-promoter communication. Enhancers
are often located far from their target gene promoters within the
noncoding genome, which makes their identification challenging.
Using statistical models, such as ChromHMM, we can infer enhancer
locations by studying multiple histone modifications obtained by the
ChIP-seq technology. However, ChIP-seq requires large cell numbers
(~10M), which is not compatible with clinical samples. The Assay for
Transposase Accessible Chromatin (ATAC-seq) is an alternative assay
to generate chromatin accessibility maps from 500–5,000 cells, mak-
ing this an ideal approach to study enhancers in clinical samples.
Here we developed a machine-learning model to infer the entire rep-
ertoire of enhancers from ATAC-seq open chromatin profiles.
Methods: We conduct our analysis on ATAC-seq data generated from
GM12878 human lymphoblastoid cell line and CD4+ T-cells. From these
samples, we extracted i) ATAC-seq features, e.g., peak strength; ii) DNA
sequence based features, e.g., conservation scores; and iii) TF binding
features using footprinting algorithms and compiled a comprehensive
dataset. We applied Random Forest algorithm on this data to predict
reference enhancers obtained from ChromHMM models.
Results: Our final data include ~60K ATAC-seq peaks and 490 features
and a class indicating chromatin state obtained via ChromHMM. Ran-
dom Forest based model predicted enhancer sequences with 74.8%
sensitivity and 73.8% specificity. We also showed that the most import-
ant features for accurately predicting enhancer sequences include
ATAC-seq based features and certain TF binding profiles.
Conclusion: The present study demonstrated that prediction of regula-
tory elements using ATAC-seq data alone is comparable to ChromHMM
predictions. It is noteworthy that ChromHMM states are also predictions
and the actual performance of ATAC-seq based model needs to be
tested on experimentally validated enhancers. Our future work includes
comparing our predictions with known enhancers from public data-
bases such as FANTOM5 and Vista enhancers.
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Objectives: Target enrichment, coupled with next-generation se-
quencing, enables the interrogation of specific targets of interest at a
level of sensitivity that is typically cost-prohibitive with whole genome
sequencing. However, the drawbacks to target enrichment generally in-
clude longer and more complex library preparation workflows or a loss
of the ability to detect PCR duplicates. Here we present DIRECT target
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enrichment, a unique and highly specific method for hybridization-
based target enrichment that incorporates the use of unique molecular
indexes in a simple, one-day protocol.
Methods: DNA was isolated from fresh frozen tissue, FFPE samples,
and liquid biopsies followed by enrichment of 36 kb of cancer-
related targets with the DIRECT enrichment method. Combined with
unique molecule barcoding and Illumina sequencing, variants were
detected and frequencies reported using common variant callers.
Results: Application of DIRECT target enrichment across different
DNA sample types show similar results, with no loss in specificity or
sensitivity across DNA isolated from different sources. Somatic varia-
tions can be detected with high sensitivity using as little as 50 ng of
input DNA, and libraries can be made with as little as 10 ng of start-
ing material for the detection of genetic variations.
Conclusion: DIRECT target enrichment enables the highly specific cap-
ture of regions of interest within 7 hours and with low amounts of
starting material. As a result, this method can easily be applied to a var-
iety of applications for which time and sample amount may be limiting.
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Objectives: This Poster focuses on the performance of both D5000
ScreenTape assays with respect to the accuracy and precision of quanti-
fication and sizing, as well as the sensitivity of these assays. Data analysis
for quantification and molarity determination was compared against the
corresponding assay for the Agilent 2100 Bioanalyzer system. Addition-
ally, performance of both the D5000 and High Sensitivity D5000 assays
on the 4200 TapeStation was compared to the 2200 TapeStation system.
Methods: The 4200 and 2200 TapeStation systems were used with
the D5000 and High Sensitivity D5000 ScreenTape assays.
Results: Data is presented that prove the specifications of sensitivity,
reproducibility, accuracy and linearity of the new D5000 assay for the
Agilent 4200 TapeStation system.
Conclusion: This Poster shows that the Agilent D5000 ScreenTape
and Agilent High Sensitivity D5000 ScreenTape assays for the Agilent
4200 TapeStation system provide highly accurate and reproducible
sizing and quantification of DNA fragments ranging from 100 to
5,000 bp. Furthermore, it demonstrates that the assays can also be
applied to determine the DNA average region size, molarity, and con-
centration of distributed DNA smears. The sizing, concentration, and
molarity results highly correlate with the data obtained from equiva-
lent assays on the Agilent 2100 Bioanalyzer system. In addition,
D5000 and High Sensitivity D5000 ScreenTape assays show equiva-
lent performance in the 4200 and Agilent 2200 TapeStation systems.
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Objectives: ClinVar archives submitted interpretations of the medical
importance of human variants, standardizes content, and aggregates
data from multiple sources to facilitate peer review and track revisions.
Methods: Interpretations are provided by clinical testing laboratories,
research laboratories, OMIM®, GeneReviews™, locus-specific data-
bases, expert panels and organizations that provide practice guide-
lines. ClinVar integrates those data with information from other NCBI
databases such as dbSNP, dbVar, Gene, and MedGen.
Results: The ClinVar website can be searched with gene symbols,
variant names including HGVS expressions, rs numbers, and diseases
or phenotypes. Searches with many results may be narrowed with fil-
ters, such as restricting to a clinical significance, type of variant, and
more. Searching by location is facilitated by Variation Viewer, a
browser to view all NCBI variation data in a region of interest, such
as a region of structural variation. Each row of the search results
table in ClinVar links to a page for that variant(s), which has two
major sections: aggregate data and submitter-specific data. The ag-
gregate data section provides a summary of information about the
interpreted variant(s). The summary includes the review status for
the variant(s), represented with a description and a number of gold
stars, and a variation identifier, which is a unique identifier that rep-
resents the variant(s) that were interpreted. The summary also dis-
plays an overall clinical significance, which is calculated based on
interpretations provided by submitters; ClinVar staff do not curate or
review clinical significance. A list of conditions for which the variant
was interpreted is provided, as well as general information about the
variant including links to other public databases. The submitter-
specific section includes details of the assertions of clinical signifi-
cance and evidence provided by each submitter. Evidence may in-
clude citations, counts of individuals with the variant, free text
descriptions of the evidence, and more. Data is updated only by the
submitter; thus maintenance of an interpretation and the supporting
evidence is the responsibility of each submitter.
Conclusion: Those with new evidence and interpretations are en-
couraged to contribute their own data to improve content for all. An
online Submission Portal is available to upload data to ClinVar, as a
single submission or in batch. ClinVar provides monthly releases
available via FTP, and API to access specific records.
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Objectives: To the best of our knowledge, this is the first report con-
firming the structural and functional association of MUTYH mutations
(Y165C; G382D; P54S; A22V; Q63R; G45D; S136P and N43S) through
In-silico approach.
Methods: We retrieved clinical records of MUTYH for multiple aden-
omas, test unit Code 84304 from the Mayo Medical Laboratory, USA.
The nonsynonymous single nucleotide polymorphisms (nsSNPs) may
alter the structure or function of expressed proteins, and therefore
have an effect on disease outcome. In order to evaluate the pheno-
typic effects of nsSNPs in human DNA repair genes, we studied the
polymorphism in terms of various functional properties.
The molecular origin of disease-related phenotypes was caused by
six mutations in MUTYH, and that were associated with heritable pre-
disposition of colon and stomach cancer syndrome of FAP.
Results: We confirmed that MAP was inherited in an autosomal reces-
sive pattern due to the mutations in Mutyh (P54S, A22V, Q63R, G45D,
S136P and N43S), hence both copies of the gene become inactivated
during disease occurance. The parents of an individual with an
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autosomal recessive condition may serve as carriers, each harboring
one copy of the mutated gene without showing signs and symptoms
of MAP. The MUTYH protein interacts with six partners, but only four of
these proteins showed direct physical interactions in our study. These
proteins were hMSH6, hPCNA, hRPA1, and hAPEX1. We also for the first
time examined specific interactions of these protein partners with MAP
associated MUTYH mutants using molecular dynamics simulations.
These approaches provided tools for exploration of the conformational
energy landscape accessible to these protein partners. The study also
determined the impact before and after energy minimization of
protein-protein interaction (PPI) and binding affinities of MUTYH wild
type and mutant forms, including interactions with other proteins.
Taken together, this study has provided innovative insights into the
role of MUTYH and its interacting proteins in MAP.
Conclusion: This study provides interesting information and will open
up a fresh avenue for the FAP researchers. We also strongly believe that
the identified important features of the HMUTYH mutations through
our In-silico study will support further In vitro studies in future.
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Objectives: GVHD remains the major cause of morbidity and mortal-
ity after allogeneic stem cell transplantation. This is particularly true
for intestinal GVHD, therefore new methods are urgently needed.
One approach is the reduction of pathogenic bacteria.
Methods: Using a haploidentical murine model, B6D2F1 mice condi-
tioned with total body irradiation (TBI) received bone marrow cells
and splenocytes from either syngeneic (B6D2F1) or allogeneic
(C57BL/6) donors. After that, animals received from day -2 until day
+28 chow with egg yolk (IgY) containing antibodies again E. coli, S.
typhimurium and C. perfringens (in alternative protocol, mice re-
ceived chow from day -2 until day 15). As control the mice received
chow without egg yolk. After treatment the effect on the severity of
aGVHD, cytokines, chemokines and pathogen-associated molecular
patterns products (PAMP) were analyzed. Furthermore the bacterial
load and microbial constitution in the stool were determined using
real time PCR and new generation sequencing method.
Results: Animals received IgY chow showed reduced GVHD severity,
improved survival and less organ damages compared to control ani-
mals. The improvement was associated with significantly diminished
expression of TNF, IL-2 and IL-6 levels in the serum and correlated
with decreased bacteria load in the stool, especially E. coli. Interest-
ingly, the bacterium L. reuteri showed increased load in IgY treated
animals. This result is in line with early works showed that Lactubacil-
lus mediated protection again aGVHD (1, 2). The expression of TLR2,
4 and NOD2 was also reduced in the gut of IgY mice.
Conclusion: Feed pellets with egg yolk containing chicken antibodies
(IgY) improved GVHD and reduced the cytokine, chemokine and
PAMP expression. Furthermore IgY antibodies decreased the patho-
genic and improved the probiotic bacteria in the colon.
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Objectives: Familial hypercholesterolemia (FH) is most commonly
caused by variants in the LDL receptor (LDLR) gene. Herein, we de-
scribe a severely affected FH proband and their first-degree blood
relatives, the proband was resistant to statin therapy and was man-
aged on an apheresis program.
Methods: Genetic screening for the LDLR variants was performed by
exon sequencing analysis. Using a bioinformatics approach we theor-
etically explored the putative structure of the wild type and mutant
LDLR protein and the implication of structural changes on the possi-
bility of LDLR dimer formation.
Results: We identified a compound heterozygous mutation with
missense c.1731G>T, p.(W577C) and frameshift c.2027delG,
p.(G676Afs*33) variants at exons 12 and 14 of the LDLR gene respect-
ively in a proband of a Saudi family. DNA sequencing of LDLR from
the parents demonstrated that the missense variant was inherited
from the mother and frameshift variant was inherited from the
father. The frameshift variant resulted in a stop signal 33 codons
downstream of the deletion, which most likely lead to a truncated
protein that lacks important functional domains, including the trans-
membrane domain and the cytoplasmic tail domain. The missense
variant is also predicted to be likely pathogenic and affect EGF-
precursor homology domain of the LDLR protein. The segregation
pattern of the variants is consistent with the lipid profile, suggesting
a more severe FH phenotype when the variants are in the compound
heterozygous state. We also describe a three dimensional homology
model of LDLR structure and examine the consequence of the mis-
sense and frameshift variants, as this could affect the LDLR structure
in a region involved in dimer formation, and protein stability.
Conclusion: The finding of a compound heterozygous mutation
causing severe FH phenotype is important for the genotype-
phenotype correlation. Furthermore, provided bioinformatics based
structural analysis of the mutant protein and its molecular conse-
quences on the physiology of FH that could facilitate developing
mechanistic models of LDLR function. These results also enlarge the
spectrum of FH-causative LDLR variants in the Arab population, in-
cluding the Saudi population.
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